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Melanoma skin cancer 
 
The skin, the biggest human organ, is continuously self-renewing and covers 
the surface of the body, separating it from the outside world. It provides 
protection against external agents such as mechanical and chemical 
aggressions such as heat, infections, water, and electromagnetic radiation. Is 
divided into two main structural compartments: the epidermis or epithelial 
component coating on the surface, and the in-depth dermis or connective 
component of nutrition. Both skin compartments cooperate in the formation 
of a highly specialized matrix structure, the basement membrane, which 
physically separates the two compartments, providing a stabilizing and 
dynamic interface (Proksch et al. 2008). 
Melanoma is the most aggressive type of skin cancer, which arises from 
melanocytes, melanin-producing cells located in the bottom layer (the 
stratum basale) of the skin's epidermis. The highest rates of incidence of 
melanoma can be found in North America, Australia and part of Europe. 
From the latest data of the International Agency for Cancer Research 
regarding 2012, 232.130 new cases of melanoma were detected and 24% of 
the diagnosed patients died (Ferlay et al. 2013). 
Cancer can spread through tissue, the lymph system, and the blood. When it 
spreads through tissue, it starts growing into nearby areas. When cancer cells 
break away from where they began (the primary tumor) and travel through 
the lymph system or blood to other parts of the body where they start 
forming a metastatic tumor, it is called metastasis. As for other cancers, the 
main cause of death in melanoma is the widespread metastasis (Chambers et 
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al. 2002). 
Different types of treatment are available for patients with melanoma. 
Surgery to remove the tumor is the primary treatment of all stages of 
melanoma. Wide local excision can be performed to remove the melanoma 
and some of the normal tissue around it. Normally, during surgery the 
sentinel lymph node (the first lymph node the cancer is likely to spread to 
from the tumor) is removed and biopsied. A marker (radioactive substance 
and/or blue dye) is injected near the tumor. The marker flows through the 
lymph ducts to the lymph nodes and the first lymph node to receive the 
substance or dye is removed. After evaluating the presence of cancer cells, 
the pathologist decides if is necessary to remove more lymph nodes or not. 
Skin grafting (taking skin from another part of the body to replace the skin 
that is removed) may be done to cover the wound caused by surgery (Essner 
et al. 2004). 
Even if all the melanoma is removed in surgery, most patients are offered 
chemotherapy after surgery to kill any cancer cells that are left. 
Chemotherapy given after surgery, to lower the risk that the cancer will 
relapse, is called adjuvant therapy. When chemotherapy is taken by mouth or 
injected into a vein or muscle, the drugs enter the bloodstream and can reach 
cancer cells throughout the body (systemic chemotherapy). When 
chemotherapy is placed directly into the cerebrospinal fluid, an organ, or a 
body cavity such as the abdomen, the drugs mainly affect cancer cells in 
those areas (regional chemotherapy, Krementz et al. 1994). 
Radiation therapy, using high-energy x-rays or other types of radiation to kill 
cancer cells or keep them from growing, may also be used. There are two 
types of radiation therapy: external radiation therapy uses a machine outside 
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the body to send radiation toward the cancer; and internal radiation therapy 
uses a radioactive substance sealed in needles, seeds, wires, or catheters that 
are placed directly into or near the cancer (Shuff et al. 2010). 
Targeted therapy is a type of treatment that uses drugs or other substances to 
selectively attack cancer cells. Targeted therapies usually cause less harm to 
normal cells than chemotherapy or radiation therapy do. For example, 
Vemurafenib and Dabrafenib are signal transduction inhibitors used to treat 
some patients with advanced melanoma or tumors that cannot be removed by 
surgery. These drugs block the activity of proteins made by mutated BRAF 
genes. Angiogenesis inhibitors are also being used to block the growth of 
new blood vessels that tumors need to grow (Garbe et al. 2011) 
Immunotherapy is a treatment that uses the patient’s immune system to fight 
cancer. Substances produced by patient’s body or made in a laboratory are 
used to boost, direct, or restore the body’s natural defenses against cancer. 
Interferon, interleukin-2 (IL-2), tumor necrosis factor (TNF) and ipilimumab 
are commonly used in melanoma. Interferon and TNF affect the division of 
cancer cells and can slow tumor growth. IL-2 boosts the growth and activity 
of many immune cells, especially lymphocytes. Ipilimumab is a monoclonal 
antibody that increases the immune response against melanoma cells. It 
binds to cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and blocks 
the interaction of CTLA-4 with its ligands, CD80 and CD86 (Garbe et al. 
2011)   
Immunotherapy is a type of systemic therapy used in the treatment of 
melanoma at high risk for recurrence and metastases; therefore, the 
characterization of melanoma associated antigens (MAA) is of great 
importance. MAA can be classified according to their expression pattern in 
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shared (i.e. expressed by different tumors and/or normal tissues) and unique 
(i.e., expressed only in particular melanomas). Shared MAA can be 
subdivided in three groups (Parmiani et al. 2003): differentiation antigens 
(proteins expressed both by melanoma cells and normal melanocytes), 
tumor-specific (proteins expressed by melanoma and other tumors, but not in 
normal tissues); and over-expressed antigens (generally expressed in normal 
tissues but over-expressed in melanoma and other tumors).  
Examples of differentiation antigens are Melan-A (MART-1 or - Melanoma 
Antigen Recognized by T-cells), Pmel27 protein from melanocytes (or 
gp100), tyrosinase (TYR) and the microphthalmia-associated transcription 
factor (MITF). Although the role of Melan-A and gp100 is not completely 
understood, Melan-A has recently been found to localize to vesicles, 
including melanosomes, suggesting a role in melanosome biogenesis; while 
gp100 localizes to an early melanosome trafficking compartment and may 
function in melanosome structure, biosynthesis of the melanin intermediate 
5,6-dihydroxyindole-2-carboxylic acid (DHICA), or morphogenesis of 
premelanosomes (Weinstein et al. 2014). TYR is involved in the reaction of 
melanin formation (Hearing 2011). MITF is essential for the development of 
the melanocyte lineage. Furthermore, it has been shown that transcription of 
the genes of Melan-A, gp-100 and TYR is regulated by MITF (Du et al., 
2003;. Urosevic et al., 2005). Melastatin or TPRM1 is a member of the 
transient receptor potential superfamily of ion channel proteins, and is 
important in cell-cycle control and cell survival. It is expressed by nevi and 
in situ melanomas, and its expression is down-regulated in invasive and 
metastatic melanomas (Hammock et al. 2006). 
Among the tumor-specific MAA are the members of the MAGE family, 
such as are MAGE-1 and MAGE-3, which are expressed in normal testis, 
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but its ectopic expression (i.e., in an abnormal local) is characteristic of 
malignant transformation (Urosevic et al. 2005).  
Over-expressed antigens are equally important MAA, which are 
overexpressed in melanoma. These include the adhesion molecule CD146 
(or MCAM - Melanoma cell adhesion molecule; Rapanotti et al., 2008) that 
is normally expressed in the endothelial lineage and Integrin beta-3 or CD61 
which is normally expressed on platelets. (Fang et al. 2005). It has been 
shown that patients expressing CD61 are more likely to die or relapse than 
patients with CD61-negative tumors (Hieken et al. 1996) and that CD146 is 
associated with advanced stages of melanoma (Rapanotti et al. 2008). 
Metalotranferrin (p97) is also overexpressed in melanoma when compared to 
normal melanocytes (Smith et al. 2006). Additionally, the expression of p97 
is correlated with tumor vascularization and progression, suggesting a 
proinvasive function associated with p97 in malignant tumors (Bertrand et 
al. 2006). 
 
 
Melanoma initiation, growth and heterogeneity 
 
Cancers arise via the acquisition of mutations that suppress senescence and 
promote cell division, but there are different models to explain cancer 
growth. The clonal or stochastic model (Nowell 1976) states that 
(epi)genetic changes occur over time in all tumor cells, and that cells gaining 
a selective advantage will generate clones that out-compete other clones. 
Stepwise natural selection of the fittest and most aggressive cells would 
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facilitate tumor progression in a linear stochastic manner (Nowell 1976). The 
cancer stem-cell model (Reya et al. 2011) suggests that only a subpopulation 
of cells within the tumor, the cancer stem cells (CSC) or Melanoma-
initiating cells (MIC) in the case of melanoma, have the capacity to 
regenerate and maintain a tumor in vivo. The bulk of the heterogeneous 
tumor cell population does not share these properties and lacks the ability to 
be tumorigenic (Reya et al. 2011).  
To the moment, MIC have been shown to express the stem cell markers 
CD133 (Frank et al. 2005, Klein et al. 2007, Monzani et al. 2007, Al Dhaybi 
et al. 2010), CD20 (Fang et al. 2005) and ABC transporters, like MDR1, 
ABCG2 and ABCB5 (Zabierowski and Herlyn 2008a, Monzani et al. 2007, 
Schatton et al. 2008, Keshet et al. 2008).  
MIC also exhibit other stem-cell functional characteristics, like side-
population (Zabierowski et al. 2008a) and sustain the stem-cell population 
while giving rise to progenitor cells that may or may not attain the capacity 
to self-renewing. These progenitor and trans-amplifying cells can give rise to 
differentiating clones of varying dominance that contribute to the overall 
tumor heterogeneity found in melanomas. MIC are also thought to play an 
important role in the cancer metastasis (Visvader et al. 2008). Therefore, 
understanding the biology of MIC is of great importance to the identification 
of possible molecular targets and development of novel therapies. 
CD133 or prominin 1 is a glycoprotein which is found in the protrusions of 
the plasma membrane of epithelial cells, and is thought to play an important 
role as organizer of the plasma membrane topology and maintenance of its 
correct lipid composition (Mizrak et al. 2008). It is normally expressed in 
undifferentiated cells like endothelial progenitor cells, hematopoietic stem 
Introduction 
 
 
29 
cells and prostate epithelial stem cells, but also in tumor cells of numerous 
solid tumors like brain, prostate, pancreas and melanoma (Zabierowski and 
Herlyn 2008b, Al Dhaybi et al. 2010).  
CD20 is an antigen specific of the mammalian immune system, which has an 
important function in the development and differentiation of B lymphocytes 
to plasma cells. It is expressed in B lymphocytes of sane individuals but it 
has also been found in numerous cancers, like lymphomas, leukemia and 
melanoma (Fang et al. 2005). A recent study, using mouse xenografts, 
demonstrated the importance of a small subpopulation of melanoma CD20+ 
cells. Engineered T cells produced to target specifically CD20+ melanoma 
cells were capable to eradicate established melanoma and significantly 
improved tumor-free survival (Schmidt et al. 2011).  
CD34, a characteristic haematopoietic stem cell marker, has also been used, 
to a smaller extent, for the identification of MICs (Bongiorno et al. 2008). 
CD90 or thymocyte differentiation antigen 1 (Thy-1) can normally be found 
in precursor of T cells in the thymus, on the surface of neurons, subsets of 
fibroblasts, endothelial cells, mesangial cells and some hematopoietic cells 
(Bradley et al. 2009). It plays an important role in the cell-cell and cell-
matrix interactions and, in melanoma, also promotes the migration and 
adhesion of melanoma cells to endothelium (Rege et al. 2006). Its over-
expression has also been associated to prostate cancer (True et al. 2010), 
hepatocellular carcinoma (Lu et al. 2011) and also in spindle cell melanoma 
(Winnepenninckx et al. 2003). 
CD117, also known as tyrosine-protein kinase Kit or stem cell growth factor 
receptor, is normally expressed in subsets of hematopoietic stem cells, germ 
cells, cajal cells of the gastrointestinal tract, mast cells and melanocytes 
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(Miettinen et al. 2005). Furthermore, CD117-mediated pathways are of great 
importance in melanocyte physiology, influencing melanogenesis, 
proliferation, migration, and survival of these cells (Alexeev et al. 2006). 
Mutations in this gene are associated with some cancers like gastrointestinal 
stromal tumors, mast cell disease, acute myelogenous leukemia, piebaldism 
and also melanoma (Miettinen et al. 2005, Woodman et al. 2010).  
Nerve growth factor receptor (NGFR) or CD271 was found on melanoma 
cells. The groups of Boiko and Civenni demonstrated, using different  
xenotransplantation models, preferential tumor formation by CD271+  
melanoma cells isolated from patient samples (Boiko et al. 2010, Civenni et 
al. 2011). Furthermore, coexpression of ABCB5 and CD271 was found in 
clinical melanoma specimens (Frank et al. 2011). 
Nestin, a class VI intermediate filament protein and TUJ1 (neuronal ßIII 
Tubulin), which are normally described as neural stem cell markers have 
also been found in melanoma. Nestin expression has been associated to poor 
prognosis in melanoma (Piras et al. 2009). Normal melanocytes robustly 
express TUJ1 protein, which tend to decrease with melanoma progression. A 
poor disease outcome was linked to high TUJ1 expression levels in some 
cancer types, such as ovary and lung (Akasaka et al. 2009). 
ABC transporters are transmembrane proteins that use the energy of 
adenosine-5'-triphosphate (ATP) to translocate solutes through the plasma 
membrane (Higgins et al. 2001). When expressed in non-cancerigenous cells 
they facilitate the movement of endogenous compounds and contribute to 
cell detoxification, and when expressed in neoplastic cells they contribute to 
chemoresistance (Hatina et al. 2001, Gottesman et al. 2002, Chen et al. 
2009). In melanoma, ABCB5 has been identified as an important mediator of 
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chemoresistance and tumor initiation (Frank et al. 2005, Schatton et al. 
2008). Furthermore, it has also been described by the functional 
characterization of the side population (SP), that can be identified by flow 
cytometry for its capacity of pumping out fluorochromes like Hoechst 33342 
(Grichnick et al. 2006, Hadnagy et al. 2006, Dou et al. 2009). The capacity 
to pump out fluorochromes like Hoechst 33342, which is a functional 
characteristic of the SP, seems to be correlated with the expression of ABC 
transporters, and it has been demonstrated that ABCG2 is the transporter 
which contributes the most for this phenotype (Scharenberg et al. 2002). 
This SP is thought to be enriched in cells with stem cell potential (Hadnagy 
et al. 2006) and it has been found in melanoma (Grichnick et al. 2006, 
Fukunaga-Kalabis et al. 2010). 
 
 
Metastasis and melanoma aggressiveness 
 
A major factor that drives metastasis is the epithelial-to-mesenchymal 
transition (EMT), a process seen in normal embryogenesis and adopted by 
epithelial cancers and resulting in a more aggressive phenotype (Lee et al. 
2014). In EMT, polarized epithelial cells lose their associations to the 
surrounding environment and attain migratory properties of mesenchymal 
cells. The reversal of EMT, the mesenchymal-to-epithelial transition (MET), 
is the acquisition of an epithelial-like phenotype, a mechanism by which 
neoplastic cells colonize target tissues. Both EMT and MET involve 
differential regulation of cell adhesion and cytoskeletal proteins. EMT is 
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closely interrelated to the CSC model, as it may have a role in CSC-driven 
metastasis (Bao et al. 2012) For instance, EMT-induced breast cancer cells 
acquire a stem-like phenotype, and breast CSC isolated from patients have 
been found to express EMT-associated markers (Charpentier and Martin 
2013). There is evidence that EMT may also be an important process 
underlying melanoma progression. By gene expression profiling, loss of E-
cadherin with gain of N-cadherin and osteonectin (SPARC) was significantly 
associated with development of metastasis (Li et al. 2015). Also, 
overexpression of Snai2, a transcriptional repressor of proteins involved in 
cell-to-cell adhesion, was found to induce an EMT-like phenotype and 
promote melanoma cell migration.  Likewise elevated levels of the 
transcription factor Snai1 as well as fibronectin, an expression profile 
consistent with a mesenchymal phenotype, were associated with increased 
melanoma metastases in vivo (Lee et al. 2014). 
While normal melanocytes express few cell–cell adhesion receptors of the 
immunoglobulin gene superfamily of cell adhesion molecules (CAMs), 
melanoma cells show an increase in expression of melanoma cell adhesion 
molecule (MCAM/CD146, mentioned above), L1 cell adhesion molecule 
(L1-CAM, CD171), activated leukocyte cell adhesion molecule (ALCAM, 
CD166), vascular cell adhesion molecule 1 (VCAM-1, CD106) and 
intercellular cell adhesion molecule 1 (ICAM-1, CD54) (Haass et al. 2005). 
Casado and co-workers also show that melanoma cell lines express not only 
adhesion molecules that are likely to favour their interaction with cells of the 
immune system, but also their interaction with endothelial cells potentially 
increasing their invasiveness and metastatic capacity (Casado et al. 2009) 
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How the above described metastatic and migratory processes are influenced 
by chemokine–chemokine receptor engagement is not completely 
understood, though they may be the result of pleiotropic chemokine-related 
signaling acting on multiple cancer cell processes. One possible scenario is 
that chemokine receptor triggering controls selectin ligand and integrin acti- 
vity on cancer cells in a manner analogous to the chemokine receptor-
mediated control of homing receptors on leukocytes. For example, 
overexpression of CXCR4 or engagement by its ligand, CXCL12, was found 
to enhance adhesion of melanoma cells to the endothelium and to VCAM 
(Lee et al. 2014). 
Chemokines are chemoattractant cytokines which were initially 
characterized by their important role in leukocyte recruitment during 
inflammatory and immune responses (Cyster 1999). They act through the 
interaction with a subfamily of G protein-coupled receptors (Allen et al. 
2007) and the extent of the cellular response triggered by chemokines 
depends on the amount of receptor expressed at the plasma membrane, 
which is a consequence of the balance between endocytic and recycling 
pathways (Borroni et al. 2010). Several studies have shown that chemokines 
and their receptors are involved in different steps of tumorigenesis, including 
angiogenesis, tumor growth, invasion and metastasis of many human cancers 
(Kakinuma et al. 2006, Vandercappellen et al. 2008).  
Chemokines and their receptors are of great importance in the melanoma 
tumor progression (Richmond et al. 2009). The expression of CXCR4 by 
melanoma cells in primary lesions is significantly associated with the 
presence of ulceration, increased tumor thickness and higher mortality rate 
(Longo-Imedio et al. 2005). The expression of CXCR3 has been observed in 
patients with primary invasive cutaneous melanomas and there is a 
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significant association of CXCR3-positive tumor cell immunostaining with 
tumor thickness >1 mm (Monteagudo et al. 2007).  
They play an important role in the process of metastasis as they regulate 
organ selectivity (Ben-Baruch 2008). They are expressed at specific organs 
and act on tumor cells, which express the correspondent receptors, inducing 
their directed migration. Chemokines also improve tumor cell proliferation, 
survival and adhesion to microvessel walls, helping the process of 
extravasation into the target tissue (Kulbe et al. 2004, Ben-Baruch 2008). 
Indeed, it has been shown that mouse melanoma B16F10 cells constitutively 
express CXCR3, and its ligands CXCL9/Mig, CXCL10/IP-10, and 
CXCL11/I-TAC induce cellular responses in vitro, such as actin 
polymerization, migration, invasion, and cell survival (Kawada et al. 2004). 
Moreover, the expression of several chemokine receptors has been 
associated with a greater risk of developing regional and distant metastases 
(Longo-Imedio et al. 2005, Monteagudo et al. 2007) as lymph node 
metastasis (CCR7, Murakami et al. 2004; CCR10, Simonetti et al. 2006; 
CXCR3 and CXCR4, Robledo et al. 2001), pulmonary metastasis (CXCR4) 
or skin metastasis (CCR10, Murakami et al. 2004). The role in melanoma of 
the recently discovered CXCR7, which binds to CXCL11 and CXCL12 
(Burns et al. 2006) is still not clear. However, it has been shown that 
CXCR7 is involved in tumor cell growth, survival, and metastasis in several 
tumor types (Sun et al. 2010). 
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Experimental models for melanoma 
 
For most cancer types, including melanoma, human cancer cell lines have 
been one of the mostly used experimental models. They are pure, easily 
propagated and genetically manipulated while providing reproducible results 
when used with the same protocol and at the same stage (Staveren et al. 
2009).  
This model has been widely used as a disease-oriented screening model for 
new anticancer drugs as the need for high throughput and low cost means 
both for drug discovery and drug development makes human cell lines the 
most suitable model. Indeed, the panel of cell lines from the National Cancer 
Institute (NCI60), composed by 60 cancer cell lines established from 
different types of cancers, has been extensively used since it was developed 
in the late 1980s, contributing for great advances in cancer chemotherapy 
(Shoemaker 2006). Similarly, the Japanese Foundation for Cancer Research 
implemented a smaller panel of 39 cancer cell lines (JFCR39). This panel 
has 30 cell lines from the NCI60 together with 6 cell lines of stomach cancer 
for which the incidence is high in Japan, and 3 additional breast cancer cell 
lines (Kong and Yamori 2012). 
Melanoma cell lines are broadly used in immunology and immunotherapy 
studies. Therefore, it was created a database and cell bank, called ESTDAB 
(http://www.ebi.ac.uk/ipd/estdab/), which provides a freely available and 
fully searchable database of highly characterized melanoma-derived cell 
lines, which have been extensively characterized for HLA genotype and 
surface expression, oncogene and tumor antigen expression, cytokine 
secretion, surface molecule expression, adhesion to extracellular matrix 
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components, cytokine gene polymorphisms and other factors, which allows 
the researchers to choose the most adequate cell line(s) for their work. 
(Robinson et al. 2009). 
Although human cancer lines are so commonly used a major drawback is 
that often they do not resemble the original tumor from which they were 
established. This happens because cancer cells in tumors do not proliferate at 
the same rate as cultured cells. In fact, cultured cells are selected for rapid 
growth with doubling times much shorter than those of cancer cells in vivo. 
Most cancer cell lines have been maintained for decades in growth-
promoting cocktails, in monolayer as opposed to three-dimensional culture, 
and in high oxygen tension (21%, whereas physiological oxygen tension 
ranges from 2% to 5%). These conditions undoubtedly affect the cells’ 
characteristics and select for subpopulations of cells that differ dramatically 
from the predominant cells of a primary cancer (Gillet et al. 2013). Indeed, 
cell lines derived from metastases of the same melanoma has been shown to 
be genetically different (Sabatino et al. 2008). Thus cell lines derived from 
one clone cannot be representative of this diversity. Furthermore, the 
complexity of biological processes often requires in vivo analysis, specially 
in cancer where the microenvironment surrounding the malignant cells is of 
utmost importance.   
To surpass some of these limitations, several mouse melanoma models have 
been developed which include: (i) xenotransplantation models; (ii) syngeneic 
transplantation models; and (iii) models involving genetically modified 
animals (Becker et al. 2010). The relevance of each particular model 
depends on how closely it represents the genetic and epigenetic aberrations, 
histology, physiological effects and metastatic pattern observed in human 
melanoma. Although genetically modified mice have been helpful in leading 
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to a better understanding of the molecular mechanisms involved in tumor 
initiation and are currently receiving most of the attention, they have been 
less successful in modeling advanced metastatic cancer (Larue and 
Beermann 2007).  
Metastases are the main determinants of the clinical course of melanoma and 
patient survival, and are thus the target of systemic therapy. Human 
melanoma metastasizes preferentially into lymph nodes, lung, liver or brain. 
In this regard, xenotransplantation models, based on immunocompromised 
mice, are particularly successful in mimicking advanced, metastatic 
melanoma as their diminished ability to mount an effective immune response 
allows the growth of human melanomas and the expression of malignant 
properties (such as preferential colonization of certain organs, Zaidi et al. 
2008). However, in these models, the role of the immune system, either 
fighting or promoting cancer, is not considered at all. Nevertheless, there are 
some types of immunocompromised mice, like the athymic nude mice, that 
are not severely immunocompromised, they lack T cells but the B cells, 
dendritic cells and granulocytes are all relatively intact, and there is a 
compensatory increase in both natural killer (NK)-cell activity and 
tumoricidal macrophages in these mice. Then, it is expectable that, by the 
time these metastatic lesions are surgically removed or biopsied, the tumor 
has already escaped immune surveillance and cell killing by the immune 
cells. 
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Tools for cell and molecular biology research 
 
Flow cytometry (FCM) measures optical and fluorescence characteristics of 
single cells (or any other particle, including nuclei, microorganisms, 
chromosome preparations, and latex beads). Physical properties, such as size 
(represented by forward angle light scatter) and internal complexity 
(represented by right-angle scatter) can resolve certain cell populations. 
Fluorescent dyes may bind or intercalate with different cellular components 
such as DNA or RNA. Additionally, antibodies conjugated to fluorescent 
dyes can bind specific proteins on cell membranes or inside cells. When 
labeled cells are passed by a light source, the fluorescent molecules are 
excited to a higher energy state. Upon returning to their resting states, the 
fluorochromes emit light energy at higher wavelengths. The use of multiple 
fluorochromes, allows several cell properties to be measured simultaneously. 
Furthermore, FCM can be used in some systems (cell sorters) to physically 
separate individual cells or particles according to their properties. 
Consequently, FCM is unique in that multiple biological parameters can be 
quantified simultaneously on a single-particle basis, while up to thousands of 
events per second may be examined. As a result, large and heterogeneous 
cell populations are described based on the biometric properties of their 
individuals (O'Connor et al. 2001). 
For all stated above, FCM has evident advantages over other conventional 
techniques of cellular biology and biochemical analysis methodologies (like 
western blot and immunocytochemistry techniques), specially for 
quantifying surface protein expression. Very importantly, FCM is a single 
cell based quantification and proteins located at the cell surface remain intact 
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as there is no need neither to lyse the cells to extract all the proteins, nor to 
fix and/or permeabilize the cells. This is of extreme importance to the study 
of characteristic surface markers in oncology research. 
Polymerase chain reaction (PCR)-based techniques, namely real-time PCR, 
are also very powerful, sensitive and important for cancer research as they 
allow the acquisition of genetic information through the specific 
amplification of nucleic acid sequences starting with a very low number of 
target copies. This quantification of gene expression by malignant cells is of 
paramount importance to investigate gene patterns responsible for cancer 
development, progression and response/resistance to treatment but  also to 
understand the heterogeneity of these complex systems (Mocellin et al. 
2003). 
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Hypothesis and Objectives 
Human melanoma is a highly heterogeneous cancer constituted by 
subpopulations of tumoral cells with distinct phenotypes. These 
subpopulations grant the biological complexity responsible for phenomena 
of self-renewal, tumor initiation, differentiation, progression and resistance 
to therapy. In this context we propose the following hypothesis: 
- Human melanoma cell lines established from primary and metastatic 
tumors from different locations will allow us to determine the intra- and 
inter-tumoral heterogeneity of melanoma by profiling the protein and gene 
expression using the quantitative techniques of flow cytometry and real-time 
PCR. 
- Xenotransplantation of human melanoma cell lines into athymic nude mice 
will allow us to obtain an "in vivo culture" and assess the dynamic variations 
of protein and gene expression after this selective pressure. 
To validate these hypotheses, the following objectives are proposed: 
- Characterize phenotypical and functionally human melanoma cell lines 
established from primary and metastatic tumors, through the quantification 
of protein and gene expression, of melanoma associated antigens, cancer 
stem cell markers, pluripotency stem markers, EMT markers and 
chemokines their receptors. using flow cytometry and real-time PCR. 
- Understand the dynamic variations of the gene and protein expression 
profiles after xenotransplantion of the human melanoma cell lines into 
athymic nude mice. 
- Correlate the data with the origin of the melanoma (primary or metastasis). 
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1. Biological Samples 
 
Established Melanoma Cell lines  
Thirteen established human melanoma cell lines were used, five established 
from primary tumors and eight established from metastases at different 
locations (Table 1). In addition, the human T lymphoma Hut-78 cell line was 
also included in this study as it also expresses some of the chemokine 
receptors studied (Notohamiprodjo et al 2005).  
 
Table 1. List of tested cell lines, tumor type, origin and source. DSMZ – German 
Resource Centre for Biological Material, ECACC – European Collection of Cell 
Cultures, ATCC - American Type Culture Collection, Dept. Pathology – 
Department of Pathology, University of Valencia, Valencia, Spain). 
Tumor Cell line Origin Source 
Melanoma 
IPC-298 Primary DSMZ 
Mel-Juso Primary DSMZ 
Mel-HO Primary DSMZ 
IGR-39 Primary DSMZ 
WM-115 Primary ECACC 
A-375 Skin metastasis ATCC 
MeWo Lymph node metastasis ATCC 
SK-Mel 28 Skin metastasis ATCC 
Malme-3M Lung metastasis ATCC 
SK-Mel 2 Skin metastasis ATCC 
WM-266.4 Skin metastasis
(1)
 ECACC 
IGR-37 Lymph node metastasis
(2)
 DSMZ 
Mel-RC08 § Brain metastasis Dept. Pathology 
Human T-cell 
Lymphoma 
Hut-78 Primary ECACC 
(1) Established from the same patient as cell line WM-115 
(2) Established from the same patient as cell line IGR-39 
§    Gil-Benso R. et al., Hum Cell. 2012 Jun;25(2):61-7. 
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Human tumor xenografts and derived cell lines 
The primary WM-115 and the metastatic WM-266.4 cell lines, established 
from the same patient, were inoculated into 4-6 weeks old BALB/c athymic 
nude mice (Charles River, Spain). Each mouse was inoculated with 200 µl 
containing 2x10
6
 cells. Due to different growth rates of the tumors, the 
animals inoculated with WM-266.4 were sacrificed 35 days after inoculation 
and the ones inoculated with WM-115 were sacrificed 77 days after 
inoculation. Tumors were extracted and disaggregated using 0.02% 
collagenase type II (Sigma-Aldrich). Cells were resuspended in culture 
medium. A sub-sample was immediately used in the flow cytometry 
experiments (hereafter referred as xenografts WM-115-X and WM-266.4-X) 
and the remaining were maintained in culture, in order to establish new cell 
lines after xenotransplantation. Five cell lines were obtained from different 
xenografts of WM-115 and six cell lines were derived from distinct 
xenografts of WM-266.4. These modified cell lines were named WM-115-
CX and WM-266.4-CX (CX stands for cultured xenografts). All the human 
tumor xenografts and derived cell lines were obtained from the Department 
of Pathology, University of Valencia. 
 
Culture conditions 
All melanoma cell lines grew as a monolayer, attached to a plastic substrate 
while Hut-78 grew in suspension. All cultures were grown and maintained in 
75 cm
2
 flasks, at 37ºC, in a humidified atmosphere with 5% CO2 using 
RPMI 1640 medium, supplemented with 10% fetal bovine serum inactivated 
by heat, 2 mM L-glutamine, 100 UI/mL penicillin and 100 g/mL 
streptomycin sulfate (Invitrogen).  
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2. Flow Cytometry 
 
Antibodies and fluorochromes 
All monoclonal antibodies (mAbs) against chemokine receptors were 
conjugated to phycoerytrin (PE). mAbs against CXCR3, CXCR4, CCR7 and 
their corresponding isotypic controls were purchased from BD Biosciences. 
mAbs against CXCR7 and CCR10 and their corresponding isotypic isotypic 
controls were purchased from R&D Systems. All chemokine ligands 
(CXCL9, CXL10, CXCL11, CXCL12, CCL19, CCL21, CCL27 and CCL28) 
were detected using primary mouse-anti-human mAbs with a secondary goat 
anti-mouse antibody labeled with FITC (R&D Systems).  
For the detection of melanoma biomarkers, mAbs against CD61, CD146 and 
the corresponding isotypic isotypic controls were purchased from Beckman-
Coulter. Unconjugated antibody against Melan-A, purchased from Santa 
Cruz Biotechnology, was detected using a secondary goat-anti-mouse 
antibody labeled with FITC (R&D Systems).  
For the detection of CSC and EMT biomarkers, mAbs against CD20, CD90, 
CD34, CD117 and their corresponding isotypic controls were purchased 
from Beckman-Coulter. mAbs against CD271, N-Cadherin, TUJ1 and their 
corresponding isotypic controls were purchased from BD Pharmingen. mAbs 
against ABCG2, E-Cadherin, Nestin and correspondent isotypic control were 
purchased from R&D Systems. mAb against CD133 and correspondent 
isotypic control were purchased from Mylteni Biotec. Unconjugated 
ABCB5, was purchased from Santa Cruz and was detected using a 
secondary donkey-anti-goat antibody labeled with FITC (R&D Systems).  
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The location of the studied proteins (i.e cell surface or intracellular) and the 
conditions used for their detection (type and volume of antibodies, time and 
temperature of incubation and cytometer settings) are described in Table 2A 
and B. 
The DNA intercalating fluorochromes Hoechst 33342, propidium iodide (PI) 
and 7-Aminoactinomycin D (7-AAD) were purchased from Sigma-Aldrich. 
 
Quantification of proteins with cell surface expression 
Cells at subconfluency (50–70%) were detached either with 2 mM EDTA in 
PBS (for the detection of chemokine receptors) or with accutase solution (for 
the detection of melanoma, CSC and EMT biomarkers, Sigma-Aldrich), 
washed and resuspended in culture medium at 10
6 
cells/ml. Subsequently, 
100 µl of this cell suspension were incubated with each of the mAbs and 
correspondent isotypic controls and with the unconjugated primary antibody 
for ABCB5 (using secondary antibody alone as control), according to Tables 
2A and 2B. After incubation, cells stained with conjugated antibodies were 
washed with ice-cold PBS and resuspended in 500 µl of culture medium for 
flow cytometric analysis. Cells stained with unconjugated ABCB5 were 
further stained with secondary antibody for 30 min, washed twice and 
resuspended in 500 µl of culture medium for flow cytometric analysis with a 
FC500 MCL flow cytometer (Beckman-Coulter). Additionally, when 
quantifying chemokine receptor expression, 3 µg/ml 7-AAD was added to 
the cell suspension in order to discriminate dead cells.  
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Table 2A Proteins detected by flow cytometry, their location in cells (Loc. - 
location in cells; CS – cell surface, I – intracellularly), and type of antibodies used 
for their detection.  
Protein Type Loc. Antibodies for detection 
CXCR3 
Chemokine 
receptors 
CS/I Mouse anti-human mAb-PE 
CXCR4 
CXCR7 
CCR7 
CCR10 
CXCL9 
Chemokines I 
Mouse anti-human mAb  
+ Goat anti-mouse IgG - FITC 
CXCL10 
CXCL11 
CXCL12 
CCL19 
CCL21 
CCL27 
CCL28 
Melan-A 
Melanoma 
antigens 
I 
Mouse anti-human mAb  
+ Goat anti-mouse IgG - FITC 
CD61 
CS 
Mouse anti-human mAb-PE-Cy7 
CD146 Mouse anti-human mAb-PE 
CD20 
CSC 
CS 
Mouse anti-human mAb-FITC 
CD34 Mouse anti-human mAb-PE-Cy5 
CD90 Mouse anti-human mAb-PE-Cy5 
CD117 Mouse anti-human mAb-PE-Cy5 
CD133 Mouse anti-human mAb-APC 
CD271 Mouse anti-human mAb-Alexa647 
ABCB1 Mouse anti-human mAb-PE 
ABCB5 
Goat anti-human mAb 
 + Donkey anti-goat IgG - FITC 
ABCG2 Mouse anti-human mAb-PE 
Ecad Mouse anti-human mAb-PE 
Ncad Mouse anti-human mAb-Alexa488 
Nestin 
I 
Mouse anti-human mAb-PE 
TUJ1 Mouse anti-human mAb-FITC 
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Table 2B. Proteins detected by flow cytometry and conditions for their detection 
(volume of antibodies used, time and temperature - Temp. of incubation, and 
cytometer setting for their detection). RT: room temperature. 
Protein 
Antibody 
Volume 
(µl) 
Incubation Conditions Cytometry Settings 
Temp. 
Time 
(min) 
Excitation 
(nm) 
Emission 
(nm) 
CXCR3 
5 
Ice 30 488 
575±20 
CXCR4 
CXCR7 
CCR7 
CCR10 
CXCL9 
1 525±20 
CXCL10 
CXCL11 
CXCL12 
CCL19 
CCL21 
CCL27 
CCL28 
Melan-A 5 
RT 60 
488 
525±20 
CD61 5 785±20 
CD146 4 575±20 
CD20 10 
488 
525±20 
CD34 10 675±20 
CD90 10 675±20 
CD117 2 675±20 
CD133 2 
633 675±20 
CD271 5 
ABCB1 2 
488 
575±20 
ABCB5 5 525±20 
ABCG2 10 575±20 
Ecad 5 575±20 
Ncad 5 525±20 
Nestin 5 575±20 
TUJ1 5 525±20 
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Quantification of proteins with intracellular expression 
Cells at subconfluency (50–70%) were detached either with 2 mM EDTA in 
PBS (for the detection of chemokine and their receptors) or with accutase 
solution (for the detection of melanoma and CSC biomarkers). Afterwards, 
cells were washed with PBS, fixed with 4% paraformaldehyde and 
permeabilized with 0.1% Triton/PBS adjusting cell suspension to 10
6 
cells/ml. Then, 100 µl of this cell suspension was incubated with each of the 
conjugated mAbs and the correspondent isotypic controls and with the 
unconjugated primary antibodies (using secondary antibody alone as 
control), according to Tables 2A and 2B. After incubation, cells stained with 
conjugated antibodies were washed with ice-cold PBS and resuspended in 
500 µl of ice-cold 1% BSA/PBS for flow cytometric analysis with a FC500 
MCL flow cytometer. Cells stained with unconjugated antibodies were 
further stained with secondary antibodies for 30 min, washed twice and 
resuspended in 500 µl of ice-cold 1% BSA/PBS for flow cytometric analysis 
with a FC500 MCL flow cytometer (Beckman Coulter). 
 
Chemokine secretion 
The quantification of the secretion levels of chemokine was performed in 
cell culture medium collected after 24 h of sub-culturing the cells, using the 
commercial multiplex kits MILLIPLEX™ Multi-Analyte Profiling (MAP) 
(Millipore) according to manufacturer instructions (Table 3). Furthermore, 
the secretion of IL-8, Gro and MCP-1 was quantified, as a positive control of 
the melanocytic function (Payne and Cornelius, 2002). The samples were 
subsequently analyzed using Luminex 100™ System (Luminex 
Coorporation). Briefly, this multiplex technology uses 5.6 micron 
polystyrene microspheres which are internally dyed with red and infrared 
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fluorophores. The combination of different intensities of these dyes allows 
the generation of 100 different microsphere sets, each one of them 
characterized by a unique spectral signature determined by its red/infrared 
blend. Each set of microspheres is coated with a specific antibody against an 
analyte of interest (which in this case are different proteins). These allow the 
quantification of up to 100 analytes in a single reaction tube. After the 
sample has been incubated with the microspheres it is allowed to react with a 
biotinylated antibody against the analyte of interest, and finally, this is 
incubated with streptavidin conjugated to PE, whose fluorescence is 
measured to quantify the analyte of interest.  
 
Table 3 Milliplex™ Multi-Analyte Profiling (MAP) kit and quantified analytes.  
Milliplex™ MAP kit Quantified Analytes 
Human cytokine panel I 
CXCL10/IP-10 
CCL2/MCP-1 
CXCL8/IL-8 
CXCL1-3/GRO 
Human cytokine panel II 
CXCL12 
CCL21 
CCL27 
Human cytokine panel III 
CXCL9 
CXCL11 
CCL19 
  
 
All protein quantifications (i.e. protein expression and secretion) were 
performed 24 h after sub-culturing, using cells with identical culture 
conditions. Furthermore, the quantification of cell surface expression of 
chemokine receptors and intracellular expression of chemokines and their 
receptors was performed in the same day.  
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Detection of the Side Population  
Cells at subconfluency (50–70%) were detached with 2 mM EDTA in PBS, 
washed and resuspended at 10
6 
cells/ml in culture medium supplemented 
with 10mM HEPES. Subsequently, cells were stained with 5 µg/ml Hoecsht 
33342 for 90 min at 37ºC in the dark and constant agitation (in a water bath), 
in the presence or absence of 50 µM verapamil (ABCB1 inhibitor, Sigma-
Aldrich) or 10 µM fumitremorgin C (ABCG2 inhibitor, Sigma-Aldrich). 
After incubation, cells were centrifuged at 4ºC and resuspended in cold 
culture medium supplemented with 10 mM HEPES. To exclude dead cells 
from the analysis, 5 µg/ml of PI was added prior to the analysis with a 
MoFlo Legacy high speed cell sorter (Beckman-Coulter).   
 
Instrument settings 
FC500 MCL Flow Cytometer 
This standard instrument is equipped with an air-cooled argon ion laser (488 
nm, 15mW) and a red Helium - Neon, laser (633nm, 20mW) for sample 
excitation. For detection the cytometer is equipped with two light scatter 
detectors that measure the forward scatter (FS, an estimation of cell size) and 
the side scatter (SC, an estimation of intracellular granularity/complexity), 
and five photomultiplier tubes that detect the appropriately filtered light. 
FITC and Alexa488 fluorescence were collected at emission values of 
525±20nm, PE at 575±20nm, PE-Cy5, APC, Alexa647 and 7-AAD at 
675±20nm, and PE-Cy7 at 785±20nm, all using a logarithmic amplification. 
When analyzing the cell surface expression of chemokine receptors all 
measurements were restricted to live cells by gating the cells that excluded 
7-AAD whilst when analyzing the rest of the proteins the population was 
selected based on forward and side scatter parameters. 
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MoFlo high speed cell sorter  
This cell sorter is equipped with a water cooled Enterprise II laser (488nm 
and 351nm, 30 mW). Cell morphology was analyzed with two light scatter 
detectors that measure the forward scatter (FS, estimation of cell size) and 
the side scatter (SC, estimation of intracellular granularity/complexity). 
Hoechst 33342 blue and red fluorescences were detected with the 
photomultipliers 405±30 nm and 670±20 nm, respectively, using a linear 
scale. PI was detected at 613±20 nm with logarithmic amplification. 
A biparametric plot of FS and PI fluorescence was used to select live cells 
(PI negative). Then, gating in the live cells, a biparametric plot of Hoechst 
33342 blue and red fluorescences was used to assess the dye efflux 
characteristic of the SP. For the correct identification of this subpopulation, 
cells were also analyzed in the presence of ABCB1 and ABCG2 inhibitors 
(verapamil and fumitremorgin C, respectively) to demonstrate that the SP 
disappeared by blocking Hoecsht 33342 efflux. 
 
Luminex 100™ System  
This instrument is equipped with two lasers, a classification laser (635 nm, 
25 mW), to excite the red and infrared internal dyes of the microspheres 
allowing their identification/classification (i.e. which analyte is being 
measured), and a reporter laser (532 nm, nominal output 10-15 mW, 
maximun 500 mW,) to excite PE allowing the quantification of each analyte. 
For fluorescence detection, the instrument is equipped with a classification 
detector and doublet discriminator composed by avalanche photo diodes 
with temperature compensation, and a reporter detector composed by a 
photomultiplier tube, with a detection bandwidth of 565 – 585 nm.  
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3. Real-time PCR 
 
RNA isolation 
Established and tranfected cell lines. 2.5x10
5
 cells/well were seeded in 24 
well plates and left in culture for 24 h. RNA was then extracted using 
RNeasy Micro kit (Qiagen) according to manufactures instructions. 
Cultured xenografts cell lines. 2.5x10
5
 cells were detached, centrifuged and 
resuspended in 1000µl of RNAprotect cell reagent (Qiagen). Samples were 
kept at -20ºC until they were processed using RNeasy Micro Kit according 
to manufacture instructions. 
After RNA isolation all samples were kept at -80ºC until used. 
 
RNA quality control: yield, purity and integrity 
Three quality controls were performed on isolated RNA to determine the 
quantity (i.e. yield), purity and integrity of RNA that had been isolated. RNA 
quantity and purity were determined using NanoDrop
®
 ND-1000 UV-Vis 
Spectrophotometer (Thermo Fisher Scientific), which scans the absorbance 
from 200 nm to 350 nm, which is the relevant region for determining RNA 
concentration and purity. RNA has its absorption maximum at 260 nm and 
the ratio of the absorbance at 260 and 280 nm is a standard measurement to 
assess the RNA purity. RNA purity is considered acceptable when the ratio 
A260/A280 is within the range 1.8-2.0. To evaluate RNA integrity, samples 
were processed with Eukaryote RNA 6000 Nano Labchip kit and analysed 
with Agilent 2100 Bioanalyzer (Agilent Technologies). RNA samples were 
separated using electrophoretic separation on microfabricated chips and 
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subsequently detected via laser induced fluorescence detection. The 
bioanalyzer software generates an electropherogram and gel-like image that 
provides a detailed visual assessment of the RNA sample and displays 
results such as sample concentration and ribosomal ratio. Most importantly, 
the software provides a user independent measurement of RNA integrity, the 
RNA integrity number (RIN), which was employed to select RNA samples 
used in downstream applications. Although is common to accept a RIN 
above 5 (Derveaux et al 2010), in this study all RNAs were selected when 
samples had RIN>8 (Figure 1).  
 
Two-step Real Time PCR 
1. Reverse transcription 
RNA was reverse transcribed using QuantiTec Reverse Transcription Kit 
(Qiagen) according to manufacture instructions (Table 4). Briefly, prior to 
reverse transcription, RNA was incubated for 2 min at 42ºC with a buffer to 
eliminate genomic DNA contamination. After this procedure, the RNA 
sample was ready for reverse transcription, which was done using a master 
mix prepared from Quantiscript Reverse Transcriptase, Quantiscript RT 
Buffer (containing dNTPs and Mg
2+
), and RT Primer Mix (blend of oligo-dT 
and random primers). The entire reaction was performed at 42°C and 
afterwards inactivated at 95°C.  
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A
RIN: 6.20
B
RIN: 9.40
 
Figure 1. Examples of isolated RNA excluded and included in the gene expression 
study for having RIN<8 (A) and RIN>8 (B), respectively.  
 
 
Table 4. cDNA synthesis with integrated removal of genomic DNA contamination: 
reverse transcription conditions using QuantiTec Reverse Transcription Kit (reaction 
components and incubations). 
Step Component 
 Volume 
(µl)/reaction 
Incubation 
(Time, Temp) 
I) Genomic 
DNA 
Elimination 
gDNA Wipeout Buffer, 7x 2 
2min, 42ºC 
Template RNA Variable (1µg) 
RNase-free water  Variable 
Total volume 14 
II) Reverse 
Transcription 
Quantiscript Reverse 
Transcriptase * 
1 
15min, 42ºC 
3min, 95ºC 
Quantiscript RT Buffer, 5x § 4 
RT primer mix ǂ 1 
Template RNA 
Entire reaction 
from step I (14) 
 Total volume 20 
* Contains RNase inhibitor; § Includes Mg2+ and dNTPs; ǂ Composed by a blend of 
oligo-dT and random primers 
Methodology 
 
56 
2. Relative quantification of gene expression by real time PCR (RT-
PCR)  
RT-PCR reactions were carried out with 50 ng template cDNA, QuantiTec 
primers specific for each gene quantified (Table 5) and 1X QuantiTect 
SYBR Green PCR Master Mix (Qiagen), according to Table 6. Non-
template control reactions were performed for each gene, in order to evaluate 
unspecific amplification. Reactions were performed in a LightCycler® 480 
Real-Time PCR System (Roche Applied Science) using the cycling 
conditions shown in Table 7. Melting curve analysis of the PCR products 
was performed in the end of each experiment to verify their specificity and 
identity, and discard the formation of primer dimers.  
 
RT-PCR Analysis 
RT-PCR results were analysed using LightCycler® 480 Software, release 
1.5.0, v. 1.5.0.39 (Roche) and Ct values were extracted using the fit point 
analysis method. 
A critical step for an accurate quantification of gene expression is the 
normalization of the results to a fixed reference; that is, one that is not 
affected by the experimental conditions. Although normalizing against one 
constitutively expressed housekeeping gene is the most common method, 
there is no universal reference gene that is constant in all experimental 
conditions. Therefore, we performed RT-PCR measurements of six different 
housekeeping genes, ACTB, B2M, GAPDH, PGK1, RPL13A and RRN18S, 
with all samples and then analysed the results with geNorm software 
(PrimerDesign). This software ranks the housekeeping genes according to 
their stability within the samples tested and recommends the optimal number 
of housekeeping genes to be used for optimal normalization (Vandesompele 
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et al 2002). For each data set analysed the most stable housekeeping genes 
were chosen. For comparison of relative gene expression of chemokine and 
chemokine receptors between the different melanoma cell lines and Hut-78, 
RPL13A, RRN18S, ACTB and PGK1 were used in the analysis (Figure 2); 
for the analysis of the transfected cell lines RRN18S, B2M and GAPDH 
were used; for the analysis of the xenotransplants RRN18S, PGK1, ACTB 
and RPL13A were used; and for all other analysis RRN18S, PGK1, ACTB, 
RPL13A and B2M were used. 
 
For comparison of relative gene expression between the different melanoma 
cell lines, ΔCt was calculated as follows: 
ΔCt(sampleA)  = [(Mean Ct[gene of interest] - GeometricMean Ct[HouseKeepings])(sample A)]  
 
RNA from healthy skin (Agilent Technologies) was also quantified. 
 
When analysing transfected cell lines or the cell lines obtained after 
xenotransplantation, the original cell line was used as calibrator sample, and 
therefore, 2
−ΔΔCt
 method was used (Livak & Schmittgen 2001), where: 
ΔΔCt(sampleA) = [(Mean Ct[gene of interest] - GeometricMean Ct[HouseKeepings])(sample A)]  
- [(Mean Ct[gene of interest] - GeometricMean Ct[HouseKeepings])(calibrator sample)]  
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Table 5. Genes quantified by RT-PCR using Quantitec Primer Assays (Qiagen). 
Oficial 
Symbol 
Oficial Gene Name 
Catalog 
Number 
Detected 
transcript 
(GenBank ID) 
CXCR3 chemokine (C-X-C motif) receptor 3 QT00213493 NM_001504 
CXCR4 chemokine (C-X-C motif) receptor 4 QT00223188 NM_001008540 
CXCR7 chemokine (C-X-C motif) receptor 7 QT00069650 NM_020311 
CCR7 chemokine (C-C motif) receptor 7 QT01666686 NM_001838 
CCR10 chemokine (C-C motif) receptor 10 QT00034783 NM_016602 
CXCL9 chemokine (C-X-C motif) ligand 9 QT00013461 NM_002416 
CXCL10 chemokine (C-X-C motif) ligand 10 QT01003065 NM_001565 
CXCL11 chemokine (C-X-C motif) ligand 11 QT02394644 NM_005409 
CXCL12 chemokine (C-X-C motif) ligand 12 QT00087591 NM_000609 
CCL19 chemokine (C-C motif) ligand 19 QT01157359 NM_006274 
CCL21 chemokine (C-C motif) ligand 21 QT01157366 NM_002989 
CCL27 chemokine (C-C motif) ligand 27 QT00231399 NM_006664 
CCL28 chemokine (C-C motif) ligand 28 QT01673287 NM_019846 
MITF 
microphthalmia-associated 
transcription factor 
QT00037737 NM_000248 
PMEL premelanosome protein QT00016149 NM_006928 
MLANA melan-A QT00028364 NM_005511 
MCAM melanoma cell adhesion molecule QT00079842 NM_006500 
TPRM1 
transient receptor potential cation 
channel, subfamily M, member 1 
QT00031087 NM_002420 
MFI2 antigen p97 (melanoma associated) QT00034174 NM_005929 
MAGEA1 melanoma antigen family A, 1 QT01669430 NM_004988 
MAGEA3 melanoma antigen family A, 3 QT01841224 NM_005362 
ITGB3 
integrin, beta 3 (platelet glycoprotein 
IIIa, antigen CD61) 
QT00044590 NM_000212 
TYR 
tyrosinase (oculocutaneous albinism 
IA) 
QT00080815 NM_000372 
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Oficial 
Symbol 
Oficial Gene Name 
Catalog 
Number 
Detected 
transcript 
(GenBank ID) 
ABCB1 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
QT00081928 NM_000927 
ABCG2 
ATP-binding cassette, sub-family G 
(WHITE), member 2 
QT00073206 NM_004827 
ABCB5 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 5 
QT00049448 NM_178559 
PROM1 prominin 1 QT00075586 NM_006017 
CD44 CD44 molecule (Indian blood group) QT00073549 NM_000610 
KIT 
v-kit Hardy-Zuckerman 4 feline 
sarcoma viral oncogene homolog 
QT01679993 NM_000222 
CD34 CD34 molecule QT00056497 NM_001773 
NES nestin QT01015301 NM_006617 
TUBB3 tubulin, beta 3 class III QT00083713 NM_006086 
CDH1 
cadherin 1, type 1, E-cadherin 
(epithelial) 
QT00080143 NM_004360 
CDH2 
cadherin 2, type 1, N-cadherin 
(neuronal) 
QT00063196 NM_001792 
NGFR nerve growth factor receptor QT00056756 NM_002507 
VIM vimentin QT00095795 NM_003380 
THY1 Thy-1 cell surface antigen QT00023569 NM_006288 
NANOG Nanog homeobox QT01844808 NM_024865 
CASP3 
caspase 3, apoptosis-related cysteine 
peptidase 
QT00023947 NM_004346 
EPCAM epithelial cell adhesion molecule QT00000371 NM_002354 
DPPA5 
developmental pluripotency associated 
5 
QT00205968 NM_001025290 
SOX2 SRY (sex determining region Y)-box 2 QT00237601 NM_003106 
MYC 
v-myc myelocytomatosis viral 
oncogene homolog (avian) 
QT00035406 NM_002467 
ALCAM 
activated leukocyte cell adhesion 
molecule 
QT00026824 NM_001627 
KITLG KIT ligand QT00000693 NM_000899 
TNC Tenascin C QT00024409 NM_002160 
CTNNB1 
catenin (cadherin-associated protein), 
beta 1, 88kDa 
QT00077882 NM_001904 
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Oficial 
Symbol 
Oficial Gene Name 
Catalog 
Number 
Detected 
transcript 
(GenBank ID) 
VCAM1 vascular cell adhesion molecule 1 QT00018347 NM_001078 
SPARC 
secreted protein, acidic, cysteine-rich 
(osteonectin) 
QT00018620 NM_003118 
NCAM1 neural cell adhesion molecule 1 QT00071211 NM_000615 
FN1 fibronectin 1 QT00038024 NM_212474 
SPP1 secreted phosphoprotein 1 QT01008798 NM_000582 
SNAI2 snail homolog 2 (Drosophila) QT00044128 NM_003068 
SNAI1 snail homolog 1 (Drosophila) QT00010010 NM_005985 
ACTB actin, beta QT01680476 NM_001101 
B2M beta-2-microglobulin QT00088935 NM_004048 
GAPDH 
glyceraldehyde-3-phosphate 
dehydrogenase 
QT01192646 NM_002046 
PGK1 phosphoglycerate kinase 1 QT00013776 NM_000291 
RPL13A ribosomal protein L13a QT00089915 NM_012423 
RRN18S 18S ribosomal RNA QT00199367 X03205 
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Table 6. Reaction setup for two-step RT-PCR using Quantitec Primer Assays and 
50ng of template cDNA. 
Component Volume (µl) 
2x QuantiTect SYBR Green PCR Master Mix* 12.5 
10x QuantiTect Primer Assay 2.5 
Template cDNA 1 
RNase-free water 9 
Total volume 25 
 * Provides a final concentration of 2.5 mM MgCl2. 
 
 
Table 7. Cycling conditions for relative quantifications of gene expression using  
RT-PCR with LightCycler® 480 Real-Time PCR System. 
Step Time Temperature Notes 
PCR initial 
activation step 
15 min 95°C 
This step activates HotStarTaq 
DNA Polymerase 
3-step cycling:    
i. Denaturation 15 s 94°C  
ii. Annealing 30 s 55°C  
iii. Extension 30 s 72°C 
Perform fluorescence data 
collection 
Number of cycles 45 cycles  
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Figure 2. Example of the housekeeping genes expression stability determined by 
GeNorm analysis, for the analysis of chemokine and chemokine receptors in 
melanoma cell lines and Hut-78. For this data set the software recommended the use 
of the 4 most stable genes (RPL13A, RRN18S, ACTB and PGK1). 
 
 
4. Transfected cell lines 
 
Plasmids 
cDNAs for CXCR3 and CXCR4 cloned into the vector pcDNA3.1+ were 
obtained from the cDNA Resource , University of Missouri (www.cdna.org), 
and the vector alone was obtained from Invitrogen. This vector contains the 
genes for ampicillin and neomycin resistance and can therefore, be 
propagated in E. coli strains and used for the production of stably transfected 
mammalian cell lines. 
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Bacterial transformation 
One shot® TOP10 chemically competent E. coli (Invitrogen) were mixed 
with approximately 40ng of plasmid and submitted to a heat shock (30 min 
on ice, 42 s at 42ºC, in a thermoblock, and finally 2 min on ice). Afterwards, 
1 ml of lysogeny broth (LB) medium was added to each tube and incubated 
for 1 h at 37ºC. Cells were then centrifuged, resuspended in 200 µl of LB 
containing 100 µg/ml ampicillin, plated in 100 mm culture dishes containing 
LB agar with ampicillin, and left overnight at 37ºC.  
 
Plasmid “pre-amplification” 
Isolated colonies were picked using a small sterile tip and incubated in 5 ml 
of LB with ampicillin at 37ºC with constant stirring.  Prior to plasmid 
amplification the output of the transformation was evaluated. DNA of the 
transformed bacteria was extracted using High Pure Plasmid Isolation kit 
(Roche) according to the manufacture instructions and quantified using 
NanoDrop
®
. Afterwards, 100 ng of each DNA (pcDNA3.1+ alone, 
pcDNA3.1+/CXCR3 and pcDNA3.1+/CXCR4) was digested, for 1 h at 
37ºC, with the restriction enzymes EcoRI and XhoI using the appropriate 
buffer (New England BioLabs, Inc). The products of the digestion were then 
analyzed by electrophoresis. For this purpose, they were mixed with Orange 
DNA loading dye (Fermentas Life Sciences) and loaded into a 1% agarose 
gel, using the ready-to-use O’GeneRuler 1kb DNA ladder (Fermentas Life 
Sciences) as reference. 
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Plasmid amplification 
After confirming that transformed bacteria were propagating the corrected 
plasmids we proceeded with their amplification. For this, 250 µl of each 
bacteria culture (from the previous pre-amplification step) were inoculated in 
250 ml of LB with ampicillin in a 1000 ml erlenmeyer flask to ensure a 
growth medium saturated with oxygen. This bacteria culture was then 
incubated overnight, at 37ºC, with constant stirring at 200rpm in an orbital 
incubator. Cells were harvested and DNA was extracted using Plasmid DNA 
Purification Nucleobond® Xtra Maxi kit (Macherey-Nagel), according to the 
manufacture instructions, and quantified using NanoDrop
®
. 
 
 
Transfection of WM-115 and WM-266.4 
Cell lines were transfected with pcDNA3.1+ alone, pcDNA3.1+/CXCR3 and 
pcDNA3.1+/CXCR4 using Lipofectamine
®
 LTX and Plus Reagents 
(Invitrogen, Life Technologies) following the manufacture instructions. 
Optimization of transfection conditions, i.e. amount of plasmid, 
Lipofectamine
®
 LTX and Plus Reagents, was performed using 24-well plates 
as the culture format, and the condition selected was the one that exhibited 
the higher percentage of CXCR3/CXCR4 surface expression (determined as 
explained in section II, Flow Cytometry) whilst maintaining a high cell 
viability. This condition was then scaled up in order to perform the stable 
transfection. For this reason, 2.5x10
6
 cells were seeded in 100 mm culture 
dishes with normal culture medium and left to grow as explained in section I 
(Culture conditions). After 24 h, culture medium was replaced by 20 ml of 
transfection medium (RPMI 1640 medium, supplemented with 1% fetal 
bovine serum inactivated by heat, 2 mM L-glutamine, without antibiotics). 
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Briefly, 40 µg of each plasmid were diluted in 4ml of transfection medium, 
containing 40 µl of Plus Reagent and incubated for 5min at RT, followed by 
the addition of 100 µl of Lipofectamine
®
 LTX. This mixture was incubated 
for 30 min at RT, added to the culture dishes, and incubated at 37ºC in the 
CO2 incubator. Six hours after transfection, medium was changed to fresh 
transfection medium and left to grow overnight. Twenty four hours after 
transfection, cells were switched to a selective medium which was 
supplemented with 800 µg/ml Geneticin (Invitrogen). Transfected cells were 
selected and maintained in this selective medium until stable cell lines were 
obtained. 
 
Expression of CXCR3 and CXCR4 
Gene expression and surface expression of CXCR3 and CXCR4 in the 
transfected cell lines were determined as explained in section III (RT-PCR) 
and section II (Flow Cytometry), respectively. 
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5. Data analysis 
 
All measurements in cell lines were made in triplicate.  
For the quantification of proteins in flow cytometry experiments, the number 
of positive cells stained with the different antibodies was compared with the 
number of positive cells in the correspondent negative controls (isotype or 
secondary antibody). Also, the mean fluorescence index (MFI), which is the 
ratio between the mean fluorescence of samples stained with the mAb 
against the protein of interest and correspondent control (isotype or 
secondary antibody), was calculated. The differences were analyzed using 
Student’s t-test and considered significant when p<0.05. For chemokine 
secretion experiments, the concentration obtained in each sample was 
compared to the lowest standard concentration of the standard curve and the 
differences were analyzed using Student’s t-test, and considered significant 
when p<0.05. The comparison between the expression of chemokines and 
their receptors in WM-115 and in WM-266.4 and the in the cell lines 
obtained after xenotransplantation (WM-115-X and WM-266.4-X) was 
analyzed using Student’s t-test and considered significant when p<0.05. 
Gene expression data was presented as heatmaps using ∆Cts using R 
Software (package Heatmap3, Zhao et al. 2014). The similarity of gene 
expression patterns between different genes, to perform the Hierarchical 
Clustering, was assessed using the Euclidean distance as the distance method 
and complete linkage as the agglomeration method. In red are represented 
the genes that are more expressed (i.e. with lower ∆Cts), while in green are 
represented the less expressed genes (i.e., with higher ∆Cts). Genes that were 
not amplified are shown in white. 
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Spearman correlation between the data of gene expression and protein 
expression was performed using GraphPad Prim software, and considered 
significant when p<0.05. 
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1. Melanoma cell lines 
 
Melanoma associated antigens (MAA) 
 
As MAA are often used as diagnostic and prognostic markers (Weinstein et 
al. 2014), we have quantified CD61, CD146 and Melan-A by flow 
cytometry and CD61, CD146, Melan-A gp100, TYR, MITF, MAGE1, 
MAGE3, p97 and TPRM1 gene expression in our melanoma cell lines 
aiming to find patterns of expression that would allow us to group cell lines 
with similar profile and/or establish different patterns between primary and 
metastatic cell lines. 
Previous studies using flow cytometry have reported a high variability in 
MAA expression levels between cell cultures originating from various 
patients (interindividual variability) as well as differences in MAA 
expression between various clones from the same patient (intraindividual 
variability). Additionally, they have demonstrated that during the course of 
the disease, MAA expression pattern changes resulting in either loss or gain 
of a particular antigen expression (temporal variability). The loss of 
melanoma antigen expression has been associated with immune escape and 
tumour progression (Urosevic et al. 2005). 
In our study, using flow cytometry, most cell lines expressed MAA in a high 
percentage of their population. However, the level of this expression, 
represented by the mean fluorescence index (MFI), was different between 
the studied MAA and also between the studied cell lines (Table 8). 
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Table 8. Expression of Melanoma-associated antigens (MAA) in human melanoma 
cell lines. Mean percentage (%) of cells which significantly expressed (p<0.05) 
MAA; MFI represents the mean fluorescence index calculated as the ratio between 
the mean fluorescence of samples stained with the mAb anti-MAA and 
correspondent isotypic control (n =3, P – primary tumor, M – metastasis). 
Origin Cell line 
CD61 CD146 Melan-A 
% MFI % MFI % MFI 
P IPC-298 98.91 64.86 99.23 67.38 95.63 9.85 
P Mel-Juso 98.80 15.96 98.76 124.1 96.26 14.79 
P Mel-HO 98.56 119.5 99.55 93.61 98.82 44.50 
P IGR-39 4.22 1.95 27.87 1.35 43.46 2.39 
P WM-115 99.22 129.7 95.85 74.39 82.10 11.08 
M A-375 99.41 33.46 99.48 68.93 93.52 8.34 
M MeWo 95.33 12.49 1.44 1.07 98.52 53.57 
M SK-Mel28 7.74 1.93 99.42 98.84 99.01 49.11 
M Malme-3M 98.97 34.99 99.19 65.96 97.36 11.88 
M SK-Mel 2 9.03 1.86 97.60 100.7 94.07 11.24 
M WM-266-4 98.78 165.7 98.73 117.2 87.40 4.74 
M IGR-37 4.59 1.63 78.01 17.37 97.27 27.57 
M Mel-RC08 95.54 29.31 99.58 49.42 96.91 21.61 
 
 
The cell adhesion proteins CD61 and CD146 were, in general, expressed in a 
high percentage of the populations and also presented a high level of 
expression (high MFI).  The cell lines IGR-39 and IGR-37 (established from 
the same donor) expressed both proteins in a smaller population and with a 
lower level of expression. Furthermore, SK-Mel-2 and SK-Mel-28 expressed 
CD61 in a smaller population with a lower level of expression. CD146, as an 
endothelial antigen, could affect angiogenesis and promote neoplastic 
progression from local invasive to metastatic disease, by upregulation of 
metalloproteinase MMP-2 and by cell interaction among extracellular matrix 
and vascular endothelial cells (Hass et al. 2005). The only cell lines 
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expressing CD146 in a small subpopulation were IGR-39 (27.7% CD146+ 
cells) and Mewo (1.44% CD146+ cells). Rappanoti and coworkers found 
that the presence of CD146 increases the probability of a patient being in an 
advanced stage of the disease (Rappanoti et al. 2009). If we compare the 
surface expression of CD146 in pimary and metastatic tumor cell lines from 
the same patient (IGR-39 and IGR-37, respectively) we can see an increase 
in the metastatic cell line. Comparative analysis of integrin expression in 
different stages of melanoma identified the beginning of CD61 expression as 
one of the most specific markers of the transition from radial growth phase 
to vertical growth phase of primary and is strongly expressed in metastatic 
melanoma (Kuphal 2005). 
Melan-A was expressed in almost the entire population of all cell lines, with 
the exception of IGR-39 that expressed it in less than 50% of its population. 
However, the level of this protein expression was lower when compared to 
the level of expression of CD61 and CD146. Once more, an increase in the 
Melan-A expression was detected in metastatic cell line IGR-37 comparing 
with the primary cell line IGR-39. 
 
In addition to Melan-A, CD146 and CD61, which were also studied at the 
protein level, we evaluated the gene expression of MAGE1, MAGE3, gp100, 
p97, TPRM1, TYR and MITF. For comparison of relative gene expression 
between the different melanoma cell lines (and healthy skin) ΔCts were 
calculated using RRN18S, PGK1, ACTB, RPL13A and B2M as 
housekeeping genes and presented in a heatmap clustering the genes (Figure 
3). 
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Figure 3. Gene expression of melanoma-associated antigens (MAA). Relative gene 
expression is presented in a heatmap with the ΔCts calculated using RRN18S, 
PGK1, ACTB, RPL13A and B2M as housekeeping genes. Red represent genes that 
are more expressed than those in green. Genes that were not amplified are shown in 
white.  
 
 
Three main groups of genes were clustered into highly expressed in all cell 
lines (CD61, MAGE3, p97 and MITF), slightly expressed (MAGE1, CD146 
and TPRM1) and genes that were highly expressed in most of the cell lines 
but slightly expressed in IGR-39, WM-115 and A375 (Melan-A, gp100 and 
TYR). 
The members of the MAGE family are normally expressed in normal testis, 
but its ectopic expression is characteristic of malignant transformation, this 
explains why MAGE1 and MAGE3 are not detected in healthy skin. 
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Furthermore, they were both not detected in Mel-RC08 and MAGE1 was 
also not detected in IGR-37. 
A similar pattern of expression can be observed in the expression of MITF 
and the genes this transcription factor is known to control (Melan-A, gp100, 
TPRM1 and TYR). For example, IGR-39, WM-115 and A375 are the cell 
lines expressing less MITF and also expressing less Melan-A, gp100, 
TPRM1 and TYR. On the contrary, Mel-HO, Malme-3M and Mel-RC08  are 
the cell lines expressing more MITF and also expressing more Melan-A, 
gp100, TPRM1 and TYR. 
Finally, there are no significant differences in gene expression between 
primary and metastatic cell lines. 
 
For all the MAA tested at the protein level, the level of protein expression 
(represented by the MFI) correlates positively with the level of gene 
expression (represented by 2
-ΔCt
). CD146 has the best correlation (r = 0.9, p 
< 0.0001, Figure 4).  
 
 
A B C
 
Figure 4. Spearman correlation between de gene and the protein expression of 
CD61 (A), CD146 (B),  and Melan-A (C).  (* p<0.05, ** p<0.005, *** p<0.0005). 
 
r = 0.65 * 
 
r = 0.9 *** 
 
r = 0.73 ** 
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Urosevic and coworkers found an increased expression of Melan-A, 
tyrosinase and MAGE-3 in cell cultures obtained from brain metastases, 
compared to that in other metastatic sites (Urosevic et al. 2005). However,  
Mel-RC08 that is a metastatic cell line derived from a brain metastasis, and 
is included in our study, does not express MAGE3. In fact, this is the only 
cell line where we could not detect the expression of this MAA. Similarly, 
this cell line does not express MAGE1 either. Our cell lines expressing the 
highest levels of Melan-A (i.e, higher MFI, Table 8) were the primary cell 
line Mel-HO and the metastatic cell lines Mewo (derived from lymph node) 
and SK-mel-28 (derived from skin).  
SK-Mel-28 was the cell line with the highest relative gene expression of 
metalotransferrin (p97). It has been shown that gene expression knockdown 
of p97 using siRNA inhibits invasiveness of this cell line in nude mice 
(Bertrand et al. 2007). Using flow cytometry, Smith and coworkers found 
high levels of expression of p97 in SK-mel-28 and Malme-3M, moderate 
expression in A375, WM-15, IGR-37 and IGR-39, and low expression in 
IGR-39 and WM-115 (Smith et al. 2006), which is not totally in accordance 
to our results of gene expression.  
 
 
Melanoma Cancer Stem Cells 
 
The expression of a specific set of stem cell markers is a requisite for the 
isolation and characterization of the CSC population in melanoma (Fang et 
al. 2005, Frank et al. 2005, Klein et al. 2007, Mihic-Probst et al. 2007, 
Monzani et al. 2007, Schatton et al. 2008]. The purpose of our study was to 
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contribute to the characterization of these CSC in human melanoma cell 
lines. For this reason, we have analyzed, in our melanoma cell lines, the 
expression of the stem cell surface markers CD20, CD34, CD90, CD117 
(ckit), CD133, CD271, TUJ1, Nestin and the ABC transporters ABCB1, 
ABCB5 and ABCG2. We have also analyzed the existence of the side 
population (SP) and quantified the gene expression of several genes that 
might be important in the characterization of melanoma cancer stem cells 
(Tables 9-11). 
ABC transporters are transmembrane proteins that use the energy of 
adenosine-5'-triphosphate (ATP) to translocate solutes through the plasma 
membrane. They are often associated with CSC as when expressed in 
neoplasic cells they contribute to chemoresistance (Chen et al. 2009). The 
surface expression of these proteins is shown in Table 9.  
ABCB1 was detected in all cell lines, although with variable expression. In 
Mel-Juso, Mel-HO, IGR-39, WM-115, SK-Mel-28, Malme-3M, SK-Mel-2, 
WM-266-4 and Mel-RC08 it was expressed in less than 40% of the 
population. In IPC-298, A375 and Mewo it was expressed in ca. 50% of the 
population and in IGR-37 was expressed in 82% of the population. Keshet 
and co-workers also found the expression of this marker in melanoma 
samples of 10 patients, although in lower percentages (1.3% - 9.7% 
ABCB1+ cells). These authors also detected an increase of three-fold in the 
expression of this marker when melanoma samples were grown in 
melanocytic stem cells enriched conditions. Furthermore, they found a 
ABCB1+/CD117+ subpopulation (Keshet et al. 2008). 
ABCG2 was significantly expressed in almost all cell lines, with the 
exception of A375 and Mewo, but always in less than 10% of the population. 
The expression of this marker has been previously described in the WM-115 
cell line (Monzani et al. 2007). 
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Table 9. Surface expression of ABC-transporters in human melanoma cell lines. 
Mean percentage (%) of cells which significantly expressed (p<0.05) ABC-
transporters; MFI represents the mean fluorescence index calculated as the ratio 
between the mean fluorescence of samples stained with the mAb anti- ABC-
transporter and correspondent isotypic control (n =3, P – primary tumor, M – 
metastasis). 
Origin Cell line 
ABCB1 ABCB5 ABCG2 
% MFI % MFI % MFI 
P IPC-298 57.13 1.98 1.54 ns 3.23 1.15 
P Mel-Juso 35.74 2.00 2.57 1.17 5.37 1.50 
P Mel-HO 5.85 1.72 1.65 1.15 7.90 0.98 
P IGR-39 36.20 2.01 1.13 ns 1.65 1.10 
P WM-115 13.06 1.91 0.99 1.19 0.79 1.16 
M A-375 54.92 2.15 ns ns ns ns 
M MeWo 50.27 2.00 ns ns ns ns 
M SK-Mel28 5.18 6.93 1.06 1.09 0.98 1.08 
M Malme-3M 18.15 1.69 1.65 ns 1.96 ns 
M SK-Mel 2 19.58 1.98 1.28 ns 1.37 1.28 
M WM-266-4 31.39 1.60 ns ns 4.76 ns 
M IGR-37 82.42 4.55 3.56 1.24 1.68 1.51 
M Mel-RC08 7.87 4.50 ns ns 0.50 ns 
 
 
ABCB5 was expressed in less than 5% of IPC-298, Mel-Juso, Mel-HO, 
IGR-39, WM-115, SK-Mel-28, Malme-3M, SK-Mel-2 and IGR-37. This 
marker has been previously detected in 2% to 10% of the melanoma cell line 
G3361 (Frank et al. 2005), and more recently in the WM-115 cell line 
(Fukunaga-Kalabis et al. 2010). 
 
Furthermore, the level of expression of the genes encoding these proteins 
was also evaluated (Figure 5). ABCG2 is, of the 3 transporters tested, the 
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one with highest expression and is expressed in all cell lines, while ABCB1 
was found to be expressed at lower levels. Interestingly, most of the cell 
lines which express more ABCB5 were metastatic (6 out of 8) although there 
was no statistically significant differences between the two types of cell lines 
(primary vs metastatic, t-student test). Furthermore, this transporter is only 
slightly expressed in healthy skin (while ABCG2 and ABCB1 are also 
expressed in healthy skin at comparable levels to the melanoma cell lines). 
There is no correlation between the levels of gene and protein expression for 
these receptors. 
 
 
Figure 5. Gene expression of ABC-transporters and CSC markers in human 
melanoma cell lines. Relative gene expression is is presented in a heatmap with the 
ΔCts calculated using RRN18S, PGK1, ACTB, RPL13A and B2M as housekeeping 
genes. Red represent genes that are more expressed than green. Genes that were not 
amplified are shown in white.  
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Often associated with the ABC transporters is the existence of the SP 
(Hadnagy et al. 2006). Specifically, it has been shown that an increase in 
ABCB1 expression increases the SP (Bunting et al. 2000) and the 
importance of ABCG2 has also been highlighted (Scharenberg et al. 2002). 
Furthermore, an ABCB5 subpopulation has been recently described in 
melanoma cell lines within the SP (Fukunaga-Kalabis et al. 2010). 
This population, easily identified by its capacity to pump out fluorochromes 
like Hoechst 33342, was present in seven of the 13 melanoma cell lines 
studied, four with primary tumor origin and three with metastatic origin (not 
significant, Fisher exact test). Although SP was identified in a greatest 
number of primary cell lines, the average size of this subpopulation was 
highest in metastatic cell lines. In Figure 6 are representative examples of the 
SP detected in the melanoma cell lines. 
In accordance with what was previously stated regarding the correlation 
between ABC transporters and SP, in the present study, the SP+ melanoma 
cell lines with primary origin, Mel-Juso, Mel-HO, IGR-39 and WM-115, are 
also ABCB1+/ABCG2+/ABCB5+, and from the SP+ metastic melanoma 
cell lines,  Mewo is ABCB1+, Malme-3M is ABCB1+/ABCB5+ and Mel-
RC08 is ABCB1+/ABCG2+. Furthermore, in accordance with our results, 
SP has been previously found in lymph node metastatic melanoma cell lines 
(Gricknick et al. 2006) and more recently in WM-115 cell line (Fukunaga-
Kalabis et al. 2010).  
The identification of SP, although being an easy method to obtain an 
enriched stem cell population, has limitations. Hoescht 33342 toxicity 
compromises the comparison of the biological properties between the SP and 
the main population. Still, not all cells with SP phenotype are stem cells; 
therefore, this functional characterization of the stem cells should be done 
with the simultaneous stem cell markers staining (Hadnagy et al. 2006). 
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Figure 6. Side Population found in human melanoma cell lines. In A is a schematic 
dot plot showing the distribution of all the events. In B is an example of Hoecsht 
33342 extrusion blockage by verapamil and fumitremorgin C (ABCB1 and ABCG2 
inhibitors respectively) in Mel-RC08 cell line, which is an essential control for the 
correct identification of the SP phenotype and was performed for all cell lines. In C-
I are representative biparametric dot-plots of the SP found in the human melanoma 
cell lines.  
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We also analysed the expression, both at protein (Table 10) and gene (Figure 
5) level of some of the most commonly used biomarkers for CSC, namely 
CD20, CD34, CD90, CD117 and CD133.  
 
Table 10. Surface expression of commonly used CSC markers in human melanoma 
cell lines. Mean percentage (%) of cells which significantly expressed (p<0.05) CSC 
markers; MFI represents the mean fluorescence index calculated as the ratio between 
the mean fluorescence of samples stained with the mAb anti-CSC marker and 
correspondent isotypic control (n =3, O - origin: P – primary tumor, M – metastasis). 
O Cell line 
CD20 CD34 CD90 CD117 CD133 
% MFI % MFI % MFI % MFI % MFI 
P IPC-298 ns ns ns ns ns ns 59.9 3.95 ns ns 
P Mel-Juso ns ns 1.48 1.25 ns ns ns ns ns ns 
P Mel-HO ns ns ns ns ns ns 91.5 14.2 ns ns 
P IGR-39 ns ns ns ns 0.89 ns 29.1 2.09 ns ns 
P WM-115 ns ns 2.75 0.98 ns ns ns ns ns ns 
M A-375 ns ns ns ns ns ns ns ns ns ns 
M MeWo ns ns ns ns ns ns 81.5 7.75 ns ns 
M SK-Mel28 ns ns ns ns ns ns ns ns 12.2 1.57 
M Malme-3M ns ns ns ns ns ns 90.6 11.3 ns ns 
M SK-Mel 2 ns ns 0.80 1.02 1.11 ns ns ns 10.7 1.76 
M WM-266-4 ns ns 0.32 ns ns ns ns ns ns ns 
M IGR-37 ns ns 0.94 ns ns ns 67.1 8.84 ns ns 
M Mel-RC08 ns ns 1.37 1.23 ns ns 3.17 1.20 82.0 6.28 
 
 
CD20 was not found in the surface of any of our cell lines and its gene 
expression was only detected very slightly in SK-Mel-2 and Mel-RC08.  
This marker was previously detected in WM-115, both grown as 
melanospheres in embryonary stem cell medium (10.10% CD20+) or as a 
monolayer in normal culture medium (0.06%; Fang et al. 2005).  We found 
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0.12% of CD20+ WM-115 cells but without differing significantly from the 
control.  
CD34 and CD90 were found at the surface of very few cell lines and in very 
small subpopulations (<3%) although a slight gene expression was detected 
in most of the cell lines (but always at lower levels that what was detected in 
healthy skin). The cell lines with the biggest subpopulations expressing 
CD34 protein were Mel-Juso, WM-115 and Mel-RC08 (1.48%, 2.75 and 
1.37, respectively) while the cell lines SK-Mel-2, WM-266-4 and IGR-37 
have a subpopulation smaller than 1% (0.80%, 0.32% and 0.9%, 
respectively). CD90 was only detected in IGR-39 and SK-Mel-2 (0.89% and 
1.11%, respectively). 
CD133 protein was found only in metastatic cell lines, in of SK-Mel-2 
(10.67%) and SK-Mel-28 (12.23%) and in a large subpopulation of Mel-
RC08 (82.02%). However, its gene expression has also been detected in the 
other cell lines. Previously, the expression of CD133 has been described as 
being more than 80% of the cell population in the cell lines WM-115 and 
IGR39 (Monzani et al. 2007). However, we have not found CD133+ 
populations in these cell lines, in agreement with the results obtained by 
others (Zimmerer et al. 2013).  
Finally, CD117 was detected at the cell surface of 8 of the studied cell lines, 
although its gene expression was detected in cell lines that did not show 
protein expression. The expression of this marker has been previously 
detected in samples from melanoma patients (Keshet et al. 2008). Also, for 
this CSC marker there is a positive correlation between the level of protein 
expression (represented by the MFI) and the level of gene expression 
(represented by 2
-ΔCt
, Figure 7).  
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Figure 7. Spearman correlation between de gene and the protein expression of 
CD117, ** p<0.005. 
 
 
 
Other stem cell markers like TUJ1, nestin and CD271, normally used as 
neuronal stem cell markers, were analyzed (Table 11 and Figure 8).  
Although nestin was found in almost 100% of the population of the all cell 
lines, its expression was not detected in SK-Mel-28 and a low level of 
expression was found in Mel-RC08, IGR-39 and Mel-HO. 
All cell lines expressed CD271 although the size of the subpopulation was 
variable, being that Mel-HO and IGR-37 were <1% CD271+ while Mel-Juso 
was 97.90% CD271+. Nevertheless its gene expression was found in all cell 
lines. 
The protein of TUJ1 was found in the primary cell lines IPC-298 and Mel-
Juso and in the metastatic A-375, Malme-3M and SK-mel-2, although the 
subpopulation of the former was much smaller (<5%) than the latter (>70%). 
However, all cell lines highly expressed this gene. 
 
r = 0.93 ** 
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For CD271 and Nestin, the level of protein expression (represented by the 
MFI) correlates positively with the level of gene expression (represented by 
2
-ΔCt
, Figure 9). 
 
Table 11. Surface expression of neuronal stem cell markers in human melanoma 
cell lines. Mean percentage (%) of cells which significantly expressed (p<0.05) 
these CSC markers; MFI represents the mean fluorescence index calculated as the 
ratio between the mean fluorescence of samples stained with the mAb anti-CSC 
marker and correspondent isotypic control (n =3, P – primary tumor, M – 
metastasis).  
Origin Cell line 
TUJ1 Nestin CD271 
% MFI % MFI % MFI 
P IPC-298 4.77 0.80 98.71 1.27 36.86 4.86 
P Mel-Juso 1.55 1.15 99.26 190 97.90 39.87 
P Mel-HO ns ns 96.94 30.03 0.46 0.95 
P IGR-39 ns ns 98.39 35.26 4.61 1.22 
P WM-115 ns ns 98.58 320 70.84 17.56 
M A-375 97.81 7.63 98.33 368 13.57 1.54 
M MeWo ns ns 98.54 215 55.66 7.27 
M SK-Mel28 1.39 ns 99.49 92.43 4.68 1.34 
M Malme-3M 97.49 10.77 97.23 148 4.81 1.67 
M SK-Mel 2 72.84 5.23 94.57 108.8 58.56 16.73 
M WM-266-4 ns ns 98.32 169 55.50 7.72 
M IGR-37 ns ns 98.10 33.03 0.46 1.05 
M Mel-RC08 ns ns 98.65 225. 8.45 2.85 
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Figure 8. Gene expression of neuronal stem cell markers in human melanoma cell 
lines. Relative gene expression is is presented in a heatmap with the ΔCts calculated 
using RRN18S, PGK1, ACTB, RPL13A and B2M as housekeeping genes. Red 
represent genes that are more expressed than green. Genes that were not amplified 
are shown in white.  
 
 
A B
 
Figure 9. Spearman correlation between de gene and the protein expression of 
CD271 (A) and Nestin (B). ** p<0.005, ***<0.0005. 
 
r = 0.87 *** 
 
r = 0.8 ** 
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Finally, the gene expression of traditional pluripotency stem cell markers 
like OCT-4, NANOG and SOX-2, and other associated genes was also 
evaluated (Figure 10). 
OCT4, NANOG, and SOX2 are three pluripotency transcription factors that 
are well known to contribute to the reprogramming of somatic cells into an 
embryonic stem cell-like state and there is evidence that the overexpression 
of these three genes occurs in human malignancies and is relevant to tumor 
transformation, tumorigenicity, tumor metastasis (Perego et al. 2010) These 
genes are moderately expressed in melanoma cell lines. They are clustered 
together in the heatmap but SOX-2 seems to be most expressed of them 3. 
DPPA5, which has been proposed to contribute to early embryogenesis and 
may be specific marker of embryonic stem cells (Lagarkova et al. 2006), 
was the least expressed gene. In fact, it was not detected in 6 of the cell lines 
and the highest level of its expression was observed in healthy skin. 
Although caspase 3 main role is associated with apoptosis it has been 
referenced as inductive cue for stem cell differentiation (Janzen et al. 2008) 
so it was also analyzed.  It was the most expressed gene although the levels 
were comparable to healthy skin. 
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Figure 10. Gene expression of pluripotency stem cell markers in human melanoma 
cell lines. Relative gene expression is is presented in a heatmap with the ΔCts 
calculated using RRN18S, PGK1, ACTB, RPL13A and B2M as housekeeping 
genes. Red represent genes that are more expressed than green. Genes that were not 
amplified are shown in white. 
 
 
Further studies need to be done in order to fully characterize and understand 
the melanoma CSC. The co-expression of the above mentioned cell surface 
markers together with the identification of the side population along with 
other functional studies (e.g., culturing subpopulations as melanospheres) 
will, for sure, help to achieve this goal. 
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Epethelial-Mesenquimal Transition (EMT) 
 
To evaluate the EMT potential of these melanoma cell lines we quantified 
the expression of N-cadherin and E-cadherin, both at the protein (Table 12) 
and gene (Figure 11) level. Both cadherins are expressed in the surface of 
most of the cell lines with the exception of Mel-HO and Malme-3M that do 
not express N-cadherin and WM-266 that does not express E-cadherin. 
Nevertheless, both the size of the subpopulations expressing these cadherins 
and the level of their expression is variable.  
 
Table 12. Surface expression of EMT markers in human melanoma cell lines. Mean 
percentage (%) of cells which significantly expressed (p<0.05) these EMT markers; 
MFI represents the mean fluorescence index calculated as the ratio between the 
mean fluorescence of samples stained with the mAb anti-EMT marker and 
correspondent isotypic control (n =3, P – primary tumor, M – metastasis).  
Origin Cell line 
Ncad Ecad 
% MFI % MFI 
P IPC-298 64.68 2.72 1.21 ns 
P Mel-Juso 23.57 2.21 1.12 1.33 
P Mel-HO ns ns 98.68 25.50 
P IGR-39 1.05 1.18 6.74 2.15 
P WM-115 39.34 3.66 0.65 1.18 
M A-375 47.72 8.94 6.14 2.21 
M MeWo 46.72 3.33 4.03 1.71 
M SK-Mel28 7.36 1.35 10.92 3.10 
M Malme-3M ns ns 99.16 42.05 
M SK-Mel 2 1.05 1.17 5.74 2.29 
M WM-266-4 79.79 3.88 ns ns 
M IGR-37 2.71 1.25 42.22 4.02 
M Mel-RC08 61.28 2.50 16.84 2.57 
Results and Discussion 
90 
Associated with the EMT phenotype is a shift in the cadherin expression 
profile, characterized by a decrease in E-cadherin expression (which leads to 
a decrease in keratinocytes attachment) and increase in N-cadherin 
expression (which allows the attachment to fibroblasts and endothelial cells 
in the tumor stroma, Haass et al. 2005) This is in accordance to our data 
where the only two cell lines that do not express N-cadherin are almost 
100% for E-cadherine positive. Furthermore, most of the cell lines express 
more N-cadherin than E-cadherin. 
Regarding the gene expression study, we found that N-cadherin is generally 
highly expressed in most of the cell lines, being detected in lower levels in 
Mel-HO, Malme-3M and SK-Mel-2, which are cells lines where the protein 
was not detected or detected in a very small population. This lower levels are 
comparable to the level of expression detected in healthy skin. 
E-cadherin is highly expressed in almost all metastatic cell lines and in Mel-
HO, at levels comparable to the healthy skin, while it is slightly expressed in 
most primary cell lines. 
Only for N-cadherin there is a positive correlation between the level of 
protein expression (represented by the MFI) and the level of gene expression 
(represented by 2
-ΔCt
, Figure 12).  The fact that a high gene expression of E-
cadherin does not translate in protein expression is in accordance with 
previous studies stating that melanoma cell express non functional E-
cadherin (Haass et al 2005). 
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Figure 11. Gene expression of EMT markers in human melanoma cell lines. 
Relative gene expression is is presented in a heatmap with the ΔCts calculated using 
RRN18S, PGK1, ACTB, RPL13A and B2M as housekeeping genes. Red represent 
genes that are more expressed than green. Genes that were not amplified are shown 
in white.  
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Figure 12. Spearman correlation between de gene and the protein expression of N-
cadherin (A) and E-cadherin (B). * p<0.05, ***<0.0005. 
 
We also evaluated the gene expression of the adhesion molecules EpCam, 
AlCam, VCam and Ncam, and other key players in EMT, like FN1, SPARC, 
SPP1, Snai1, Snai2, TNC, CTNNB, VIM and CD44 (Figure 11). 
VIM, FN1, SPARC and CTNNB are clustered together in the heatmap as 
being the most expressed gene in all cell lines (and in healthy skin). 
On the contrary, EpCam and VCam are clustered together as being the least 
expressed genes (together with E-cadherin). 
All other genes are clustered in the third main group of genes, which are the 
genes with more variable levels of expression between the different cell 
lines. 
Although there is no statistical significance, it seems that E-cadherin and 
NCAM are differently expressed between primary and metastatic cell lines, 
being E-cadherin more expressed in primary cell lines while NCAM is more 
expressed in metastatic cell lines (Figure 13). 
r = 0.65 * 
 
Results and Discussion 
 93 
A B
 
Figure 13. Gene expression of E-cadherin (A) and NCAM (B). Differences between 
primary and metastatic cell lines were evaluated using unpaired t-student test. 
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Chemokine and Chemokine Receptors Expression 
 
Surface expression of chemokine receptors CXCR3, CXCR4, CXCR7, CCR7 
and CCR10  
 
We found that melanoma cell lines did not express or express in a low 
degree (less than 2% of the population; Table 13) the chemokine receptors 
on their cell surface. The control cell line (Hut-78) showed surface 
expression of CXCR3 (63.1%), CXCR4 (5.9%), CCR7 (3.36%) and CCR10 
(1.23%). Representative flow cytometry plots are shown in Figure 14. 
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Figure 14. Surface expression of chemokine receptors in human melanoma cell 
lines. Representative examples for the quantification of chemokine receptors surface 
expression by flow cytometry are shown. Overlaid histograms of PE fluorescence of 
specific anti-receptor monoclonal antibody (continuous red line) and correspondent 
isotypic control (discontinuous black line) are shown to represent Hut-78 with high 
percentage of CXCR3+ subpopulation (A), WM-115 with no expression of CXCR4 
(B) and IGR-39 with a small subpopulation of CXCR7+ cells (C), which is further 
illustrated in a biparametric dotplot of FS vs PE fluorescence (D). 
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Table 13. Surface expression of chemokine receptors in human melanoma cell lines. 
Mean percentage (%) of cells which significantly expressed (p<0.05) chemokine 
receptors at the cell surface; MFI represents the mean fluorescence index calculated 
as the ratio between the mean fluorescence of the positive population in the samples 
stained with the mAb anti-receptor and correspondent isotypic control (n =3, ns – 
not significant, O - origin: P – primary tumor, M – metastasis). 
 
O Cell line 
CXCR3 CXCR4 CXCR7 CCR7 CCR10 
% MFI % MFI % MFI % MFI % MFI 
P IPC-298 0.16 3.10 ns - ns - ns - 0.23 11.4 
P Mel-Juso ns - ns - 0.43 27.7 ns - 0.43 12.8 
P Mel-HO 0.07 4.83 ns - 0.36 4.91 ns - ns - 
P IGR-39 0.83 8.31 ns - 1.59 7.09 ns - 1.79 4.05 
P WM-115 0.15 5.91 ns - ns - ns - 0.11 5.09 
M A-375 ns - ns - ns - ns - ns - 
M MeWo ns - ns - ns - ns - ns - 
M SK-Mel28 ns - ns - ns - ns - ns - 
M Malme-3M ns - ns - ns - ns - ns - 
M SK-Mel 2 0.44 3.16 ns - 0.35 10.3 ns - 0.35 3.84 
M WM-266-4 ns - ns - ns - ns - ns - 
M IGR-37 0.13 3.47 ns - 0.22 14.8 ns - ns - 
M Mel-RC08 ns - ns - ns - ns - ns - 
P Hut-78 63.1 3.37 5.9 6.9 ns - 3.36 7.66 1.23 8.36 
 
 
 
 
Intracellular expression of chemokine receptors CXCR3, CXCR4, CXCR7, 
CCR7 and CCR10 in human melanoma cell lines 
 
All cell lines significantly expressed all chemokine receptors intracellularly 
(Table 14). However a great variability was found in the pattern of 
expression, depending on the cell line and receptor studied. Some receptors 
were expressed in almost the entire population of all cell lines (e.g., CXCR4) 
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while other receptors were expressed in a large subpopulation of some cell 
lines and in a small subpopulation of other cell lines (e.g. CXCR7; Table 
14).  Representative histograms are shown in Figures 15A and 15B. 
Furthermore, the level of protein expression also varied between receptors 
and cell lines. In general, CXCR4 seems to be the receptor which is more 
expressed, as can be shown by its higher values of MFI, while CCR7 appears 
to be the receptor which is expressed at lower levels, having the lowers MFI 
values (Table 14).  
 
Table 14. Intracellular expression of chemokine receptors in human melanoma cell 
lines. Mean percentage (%) of cells which significantly expressed (p<0.05) 
chemokine receptors intracellularly; MFI represents the mean fluorescence index 
calculated as the ratio between the mean fluorescence of samples stained with the 
mAb anti-receptor and correspondent isotypic control (n =3, ns – not significant, O - 
Origin: P – primary tumor, M – metastasis).  
O Cell line 
CXCR3 CXCR4 CXCR7 CCR7 CCR10 
% MFI % MFI % MFI % MFI % MFI 
P IPC-298 99.45 7.34 99.41 6.29 21.26 1.48 58.30 1.92 45.67 1.86 
P Mel-Juso 53.74 3.27 62.50 4.16 3.58 1.18 39.58 2.51 18.64 1.78 
P Mel-HO 96.71 5.28 98.99 7.82 53.07 2.21 82.49 3.13 56.36 2.26 
P IGR-39 95.73 3.73 95.76 4.04 81.82 2.59 87.87 2.43 37.51 1.70 
P WM-115 88.59 5.40 92.45 3.95 4.97 1.57 20.16 1.70 13.67 1.57 
M A-375 43.61 2.51 94.44 14.10 63.20 3.45 12.70 1.59 45.45 2.89 
M MeWo 25.02 2.21 80.60 5.98 80.65 6.59 2.58 1.32 61.27 3.53 
M SK-Mel28 56.56 2.43 93.22 8.63 73.86 5.02 1.20 1.20 65.81 2.59 
M Malme-3M 64.99 2.07 92.84 2.66 97.78 5.66 64.86 1.99 71.88 2.37 
M SK-Mel 2 96.43 6.92 98.33 15.73 33.52 2.04 78.23 2.08 96.34 4.68 
M WM-266-4 74.08 2.22 96.26 3.39 21.53 1.68 40.16 1.69 24.00 1.63 
M IGR-37 97.88 4.25 97.85 4.53 43.84 1.89 67.83 2.03 56.29 1.89 
M Mel-RC08 45.79 2.69 95.02 7.33 72.05 3.99 9.14 1.61 60.81 2.84 
P Hut-78 82.05 2.93 95.95 4.62 19.75 1.95 13.53 1.68 88.40 4.08 
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It seems that metastatic cell lines have a significant bigger subpopulation 
expressing CCR10 (p=0.0428, Figure 16A) with a higher level of expression 
(ns, Figure 16B), cells with significant higher level of CXCR7 expression 
(p=0.0430, Figure 16C), and cells with significant lower level of CCR7 
expression (p=0.0217, Figure 16D), when comparing to the primary cell 
lines. 
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Figure 15. Intracellular expression of chemokine receptors in human melanoma cell 
lines. Representative examples for the quantification of intracellular chemokine 
receptor expression by flow cytometry are shown.   Overlaid histograms of PE 
fluorescence of specific anti-receptor monoclonal antibody (continuous red line) and 
correspondent isotopic control (discontinuous black line) are shown to represent 
92% CXCR4+ WM-115 subpopulation (A) and 24% CCR10+ WM-266.4 
subpopulation (B).  
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Figure 16. Intracellular expression of CCR10 (A and B), CXCR7 (C) and CCR7 
(D). Differences between primary and metastatic cell lines were evaluated using 
unpaired t-student test (* p<0.05). 
 
 
 
Intracellular expression of chemokines CXCL9, CXCL10, CXCL11, 
CXCL12, CCL19, CCL21, CCL27 and CCL28 in human melanoma cell lines 
 
Most chemokines were expressed intracellularly in all melanoma cell lines 
(CXCL9, CXCL11, CXCL12, CCL19, CCL21 and CCL27). On the 
contrary, Hut-78 only expressed significantly CXCL9, CCL19 and CCL27 
and in smaller subpopulations than the melanoma cell lines.  CXCL10 and 
CCL28 were the chemokines expressed by fewer cells and with the lowest 
expression levels, whereas CCL19 was the chemokine with highest 
expression level (Table 15). Representative histograms are shown in Figure 
17A and 17B. 
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When comparing metastatic and primary cells lines only CCL11 seems to 
have a significant difference in the pattern of expression being expressed in a 
bigger subpopulation of the metastatic cell lines (p=0.0042, Figure 18A) and 
higher level of expression (p=0.0375, Figure 18B). 
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Figure 17. Intracellular expression of chemokines in human melanoma cell lines. 
Representative examples for the quantification of intracellular chemokine expression 
by flow cytometry are shown. Overlaid histograms of specific anti-chemokine 
policlonal antibody + FITC secondary antibody fluorescence (continuous red line) 
and correspondent control (cell with secondary antibody, discontinuous black line) 
are shown to represent 82% CXCL12+ WM-115 subpopulation (A) and 98% 
CCL27+ WM-266.4 subpopulation (B).  
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Figure 18. Intracellular expression of CXCL11 (A, percentage of positive cells, B, 
MFI). Differences between primary and metastatic cell lines were evaluated using 
unpaired t-student test (* p<0.05, ** p<0.005). 
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Gene expression of chemokines and their receptors 
 
For comparison of relative gene expression between the different melanoma 
cell lines (and Hut-78) ΔCts were calculated using RPL13A, RRN18S, 
ACTB and PGK1 as housekeeping genes and presented in a heatmap 
clustering the genes (Figure 19). 
The clustering identifies 2 main groups of genes. Most of the chemokines 
(with the exception of CXCL12 and CCL28) are grouped in the least 
expressed genes, while all the receptors are grouped in the most expressed 
genes, being, in most of the cell lines, CXCR4 the most expressed receptor. 
Interestingly CXCL12 is included in the later group along with the receptors. 
CXCL9 was not detected in any of the primary cell lines but is slightly 
expressed in most of the metastatic cell lines while CCL28, clustered 
independently in the heatmap, was not detected in most of the metastatic cell 
lines but is slightly expressed in most of the primary cell lines. 
Both for chemokine and receptors there is no correlation between the protein 
level of expression (MFI) and the gene expression. 
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Figure 19. Gene expression of chemokines and their receptors in human melanoma 
cell lines. Relative gene expression is presented in a heatmap with the ΔCts 
calculated using RPL13A, RRN18S, ACTB and PGK1 as housekeeping genes. Red 
represent genes that are more expressed than green. Genes that were not amplified 
are shown in white.  
 
 
Secretion of chemokines CXCL9, CXCL10, CXCL11, CXCL12, CCL19, 
CCL21, CCL27 and CCL28 in human melanoma cell lines 
 
CXCL10 was the only chemokine secreted in the studied melanoma cell 
lines. This chemokine was secreted in low concentrations by A375 and SK-
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Mel2 (40 pg/ml and 38 pg/ml, respectively). All melanoma cell lines 
secreted IL-8 and Gro (although in different amounts), which reassure us of 
their melanocytic function (Table 16). 
 
Table 16. Secretion of chemokines in human melanoma cell lines. Mean 
concentration (pg/ml) of secreted chemokines (n =3, § concentration bellow the 
lower limit of detection, P – primary tumor, M – metastasis). 
Origin Cell line GRO IL-8 CXCL10 
P IPC-298 936 821 § 
P Mel-Juso 3939 6663 § 
P Mel-HO 439 274 § 
P IGR-39 117 787 § 
P WM-115 341 7614 § 
M A-375 4091 5234 40 
M MeWo 1234 235 § 
M SK-Mel28 197 212 § 
M Malme-3M 217 43 § 
M Sk-Mel2 1956 7457 38 
M WM-266-4 6419 346 § 
M IGR-37 2740 117 § 
M Mel-RC08 1921 4296 § 
 
 
 
General discussion  
 
It has been previously demonstrated that chemokine receptors allow the 
directed migration towards specific organs (Muller et al. 2001). Moreover, 
the receptors CXCR4, CCR7 and CCR10 have been implicated in the 
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process of metastasis in melanoma, based on studies with animals 
(Murakami et al. 2004). Some of them, namely CXCR4, were also 
associated with metastasis in other types of neoplasms like breast, prostate, 
ovarian, colon and lung cancers (Muller et al. 2001). 
Flow cytometry is one of the methods available for immunophenotyping (i.e. 
cellular phenotyping using antibodies) which allows working with live cells 
and, therefore, to analyze cell surface expression of proteins like receptors 
(O'Connor et al. 2001). However, most studies that analyze chemokine 
receptors at the protein level have been performed using mainly 
immunohistochemistry and western blotting techniques, which do not permit 
the correct evaluation of cell surface expression. Gene expression studies 
have shown that melanoma cell lines express receptors CCR10 and CCR7, 
which could be implicated in the frequent metastasis of melanoma to skin 
and lymph nodes, respectively (Muller et al. 2001). However, these studies 
do not imply either the presence of functional receptors at the cell surface. 
We detected surface expression of CXCR3 in the cell lines IPC-298, MEL-
HO,  IGR39, WM-115, SK-Mel 2, and IGR-37, surface expression of 
CXCR7 in the cell lines Mel-Juso, MEL-HO, MEL-HO, IGR-39, SK-Mel 2, 
and IGR-37, and surface expression of CCR10 in the cell lines IPC-298, 
Mel-Juso, IGR-39, WM-115 and SK-Mel2. However, in all cases this 
expression was only detected in a small subpopulation of cells (less than 
2%). Our results differ from a study that describes functional plasma 
membrane CXCR4 in the cell lines MeWo and A375 (Robledo et al. 2001).  
All cell lines significantly expressed all the receptors intracellularly, 
although there was significant variability in the pattern of expression 
between the different cell lines. As the extent of the cellular response 
triggered by chemokines depends on the amount of receptor expressed at the 
plasma membrane the intracellular localization could affect different steps of 
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tumorigenesis, including angiogenesis, tumor growth, invasion and 
metastasis (Kakinuma and Hwang 2006,  Vandercappellen et al. 2008). The 
intracellular expression of chemokine receptors, in other tumors, has been 
shown to be correlated with metastasis directed to lymph nodes and with a 
bad prognosis (e.g., CXCR4 in breast cancer (Yasuoka et al. 2008); in lung 
cancer (Na et al. 2008); in colon cancer (Speetjens et al. 2009). In the case 
of hepatocellular carcinoma the intracellular expression of CXCR4 with lack 
of its expression at the cell surface and lack of response to its ligand 
CXCL12 has been reported (Kim et al. 2008). 
In normal cells, human differentiated neurons CXCR7 protein expression is 
mostly limited to the intracellular compartment with little to no expression 
on the plasma membrane (Shimizu et al. 2011). In the case of multipotent 
mesenchymal stem cells (MSC) intracellular expression, at protein level, of 
chemokine receptors CCR1, CCR3, CXCR3, CXCR4 and CXCR6 has been 
found (Brooke et al. 2008). However, the surface expression of these 
chemokine receptors was much more restricted with only one of the 
chemokine receptors (CXCR6) displaying a strong signal. 
A major feature of solid tumor microenvironment is hypoxia, i.e. decreased 
availability of oxygen (Finger and Giaccia 2010). Indeed, there are studies 
which show an increase of chemokine receptor expression in hypoxic 
conditions. For example, an increase in CXCR4 surface expression in the 
two human breast cancer cell lines, MDA-MB-231 and MCF7, following 
exposure to hypoxia resulted in a significant increase in migration and 
invasion in response to SDF1-alpha in vitro (Cronin et al. 2010). However, 
after submitting the primary cell lines WM-115 and IGR-39, and the 
metastatic cell lines WM-266.4 and IGR-37 to hypoxic conditions, we still 
failed to find an increase in cell surface expression of the chemokine 
receptors studied (results not shown).  
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Chemokine receptors form part of the family of G-protein coupled receptors. 
The appropriate delivery of chemokine receptors to the cell surface to allow 
receptor -ligand interactions, and their subsequent retrieval from the plasma 
membrane are of fundamental importance for the regulation of their activity 
(Borroni et al. 2010, Drake et al. 2006). Both during and subsequent to 
synthesis, chemokine receptors undergo a process of maturation before 
reaching the cell membrane. They must be properly inserted into the cell 
membrane, achieve their correct folding while still resident at the 
endoplasmic reticulum, traverse from the cis- to the trans-Golgi while 
undergoing modification, and finally be targeted to the plasma membrane 
where they attain residence as mature proteins. In order for a chemokine 
receptor to transduce an extracellular signal it must both traffic to and be 
retained at the cellular surface to allow for receptor- ligand interaction. 
Multiple proteins not involved in the signal transduction cascade have been 
identified which stabilize receptor surface expression (Tan et al. 2004). Post-
translational modifications can also alter surface expression of the receptor. 
In neuroblastoma, CXCR4 surface expression requires ubiquination and 
oligomerization of the receptor (Carlisle et al. 2009). Finally, factors 
involved in the endocytic and recycling pathways could also affect the 
amount of receptor expressed at the plasma membrane (Borroni et al. 2010). 
For instance, CCR7 recycling to the cell surface has been found to be 
dependent on ubiquitination of the receptor (Schaeuble et al. 2012). 
In this work we have also quantified by flow cytometry the intracellular 
protein expression of the chemokines which activate each of the receptors 
studied: CXCL9, CXCL10 (CXCR3), CXCL11 (CXCR3 and CXCR7), 
CXCL12 (CXCR4 and CXCR7), CCL19, CCL21 (CCR7) and CCL27, 
CCL28 (CCR10). Most chemokines were expressed in all cell lines, 
although with a heterogeneous pattern. However, chemokines CXCL10 and 
CCL28 had a low or null expression in most of the cell lines (Table 15).  
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We also analyzed the secretion of chemokines in the culture medium of all 
cell lines (Table 16). From all the chemokines studied, the only chemokine 
secreted by the melanoma cell lines was CXCL10. This chemokine was 
secreted only by the cell lines A375 and SK-Mel-2 in low concentrations. As 
a positive control we also quantified the secretion of the IL-8 and Gro 
chemokines that are produced by human melanoma (Lázár-Molnár et al. 
2000). 
There are few studies that analyze chemokine expression at protein level in 
melanoma. Using immunohistochemical techniques, a correlation has been 
found between T immunoreactive cells and the expression of CCR10 and its 
ligand CCL27 in cutaneous melanocytic lesions (Simonetti et al. 2006). 
Expression of both receptor and chemokine was found in melanoma cells. 
Their results suggest that in human melanomas CCR10 and CCL27 may act 
on the ability of neoplastic cells to grow, invade tissue, disseminate to lymph 
nodes and to escape the host immune response. Recently, 
immunohistochemical expression of CXCR4, CCR7 and CCR10 and their 
ligands has been described in tumor cells from primary and metastatic 
melanomas. The CXCL12-CXCR4 and CCL27-CCR10 ratios quantified by 
real time RT-PCR were found to be significantly higher  in thin than in thick 
primary melanomas, and inversely associated with the development of 
distant metastasis (Monteagudo et al. 2012). There is evidence, based on 
experiments designed to avoid HIV-1 infection (Yang et al. 1997, Bai et al. 
1998), that expression of genetically modified chemokines (intrakines) with 
an added endoplasmic reticulum retention signal are able to avoid surface 
expression of their chemokine receptors, by interacting with the nascent 
chemokine receptors and retaining them in the endoplasmic reticulum. This 
procedure has been extended to other chemokine receptors not involved in 
HIV infection (Onai et al. 2002, Meijer et al. 2006). The transfection with 
the native chemokine without the endoplasmic retention signal also inhibited 
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viral entry as demonstrated by the inhibitory effects on the syncytium 
formation (Yang et al. 1997), suggesting that the native chemokine can also 
prevent the transport of the receptor to the cell surface. This early interaction 
of chemokines with their chemokine receptors could alter post-translational 
processes, like glycosylations (Ludwig et al. 2000), or interactions with 
escort proteins that have been found necessary for trafficking to the plasma 
membrane and for expression of the proteins on the cell surface in other 
members of the family of G-protein-coupled receptors to which chemokine 
receptors belong (Dong and Wu 2007, Achour et al. 2008), therefore 
resulting in intracellular accumulation of chemokine receptors and 
interacting chemokines. Interestingly, the only chemokine that was found to 
be secreted in two cell lines in our study, CXCL10, shows a minimal or no 
intracellular expression in the melanoma cell lines a fact that could reflect 
that it does not interact intracellularly with its receptor and therefore is not 
accumulated within the cell.  
 
 
Production of stable transfected cell lines with Chemokine Receptors 
expression  
 
As we could not find a significant surface expression of the chemokine 
receptors in our melanoma cell lines we transfected WM-115 and WM-
266.4. Stable cells lines expressing CXCR3 and CXCR4 were successfully 
produced, as shown by an increase in gene expression (Figure 20) and, most 
importantly, by a stable expression of the proteins on the cells surface 
(Figure 21). The percentage of the subpopulation with receptor expression 
was approximately 50% for WM-115-pCXCR3, WM-115-pCXCR4 and 
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WM-266-pCXCR4 and around 75% for WM-266-pCXCR3 (Figure 21). 
Furthermore, this expression was stable with cell passaging and after 
freeze/taw cycles. 
Is important to point that the higher gene expression does not correlate with 
having a higher percentage of the subpopulation of cells expressing the 
corresponding protein (Figure 20 and 21). 
 
 
 
Figure 20. CXCR3 and CXCR4 gene expression in the stable cell lines produced. 
Transfected WM-115 is showed in green; transfected WM-266 is showed in red. 
Relative gene expression was calculated using 2
−ΔΔCt
 method is presented using 
RRN18S, B2M and GAPDH as housekeeping genes and the original cell line as a 
reference sample. 
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Figure 21. Subpopulations of WM-115 (A,B) and WM-266 (C, D) expressing 
CXCR3 (A, C) and CXCR4 (B, D). Overlaid histograms of PE fluorescence of 
specific anti-receptor monoclonal antibody (continuous red line) and correspondent 
isotopic control (discontinuous black line) are shown. 
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2.  Xenografts and derived Cell lines  
 
The development of human tumor xenograft models was a big step in 
obtaining more clinically relevant tumor models. In human tumor xenografts 
the malignant cells are human, although the stromal component of the 
tumors is rodent. Furthermore, these models have the advantage that the 
hosts are readily available and it is easy to have statistically valid numbers of 
mice (with its associated costs); also many of these models are quite 
reproducible and there are a wide variety of tumor lines available to 
xenograft. Nevertheless, the hosts are immunodeficient (specifically, in our 
study they are T-cell depleted) and the tumors are grown in a nonnatural 
sites (subcutaneously or intramuscularly, in our study). 
Tumors from WM-266.4 grew faster than the ones from WM-115. The 
growth of the former was noticed after 10 days of inoculation while the 
growth of the latter was noticed after 30 days of inoculation.  
After tumor disaggregation a subset of cells (WM-115-X and WM-266.4-X) 
was used directly for quantification of the expression of some CSC markers 
and of chemokines and their receptors by flow cytometry and another 
remaining was cultured for a few passages (WM-115-CX and WM-266.4-
CX) for posterior quantification, in order to compare them with the original 
cell lines. When cultured, the cells exhibited some variability in the 
morphology and were slightly different from the original cell lines.  
Furthermore, a more detailed studied was performed in 2 cell lines derived 
from WM-115 where all markers tested for melanoma cell lines (MAA, 
CSC, EMT and chemokines and receptors) were also evaluated. 
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i)  Comparison with parental cell lines: 
Changes in stem cell characteristics after xenotransplantation of 
WM-115 and WM-266.4 cell lines  
 
Cell surface expression of CSC markers 
When compared with the parental cell lines, the tumors WM-115-X and 
WM-266.6-X and the cell lines WM-115-CX and WM-266.6-CX obtained 
after xenotransplantation exhibited differences in the surface expression of 
the ABC transporters (Figures 22 and 23). The most drastic changes were 
observed in ABCB1 surface expression (Figure 22A,B). When compared 
with the parental cell line WM-115, there was more than 4-fold increase in 
its expression in all tumors and cells lines obtained after xenotransplantation 
(Figure 22A). As for WM-266.4, there was a significant decrease in tumors 
but a significant increase in cell lines obtained after xenotransplantation 
(Figure 22B). Regarding ABCG2 expression, there was an increase in its 
expression only in WM-115-CX but not on WM-115-X, when compared 
with the parental cell line (Figure 23A). As for WM-266.4, there was a sharp 
decrease in its expression in all tumors and cell lines obtained after 
transplantation  (Figure 23B). Finnaly, ABCB5 was the ABC transporter that 
showed less variation. It was only observed a significant increase in its 
expression in WM-115-X when compared with the parental cell line (Figure 
23A). There were no significant changes in its expression when compraing 
WM-266.4 parental cell line and its derived tumors and cell lines (Figure 
23B). 
Recent evidence indicates that WM-266.4 xenografts contain a cell 
subpopulation expressing ABCB5 endowed with intrinsic chemoresistance 
(Chartrain et al. 2012).  
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Side population 
SP was analyzed in the parental cell lines and in cells cultured after 
xenotransplantation but not in tumors because of the reduced number of 
available cells. Taking into account the increase in ABCB1 expression it 
would be expectable to have an increase in the SP (Scharenberg et al. 2002). 
When compared with the parental cell line, there was a significant increase 
in the percentage of the SP in the WM-115-CX cell lines tested, which did 
not happen with the WM-266-CX cell lines. This might be due to the 
ABCG2 expression, which decreased in these cells lines when comparing to 
the parental cell line (Figure 23B). 
 
A B
 
Figure 22. Surface expression of ABCB1 in WM-115 and WM-266.4 cell lines after 
xenotransplantation. Comparison between mean percentage of positive cells in the 
original melanoma cell lines WM-115 (A) and WM-266.4 (B) and the tumors and 
cell lines obtained after xenotransplantation. Bars refer to standard error (t-student 
test to compare with original cell line; ***p<0.001). 
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Figure 23. Surface expression of ABCB5 and ABCG2 in WM-115 and WM-266.4 
cell lines after xenotransplantation. Comparison between mean percentage of 
positive cells in the original melanoma cell lines WM-115 (A) and WM-266.4 (B) 
and the tumors and cell lines obtained after xenotransplantation. Bars refer to 
standard error (t-student test to compare with original cell line; * p<0.05, 
***p<0.001). 
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ii)  Comparison with parental cell lines : 
Surface and intracellular expression of chemokines and their 
receptors in WM-115 and WM-266.4 cell lines after 
xenotransplantation 
 
Surface expression of chemokine receptors 
We xenografted the primary cell line WM-115 and the metastatic cell line 
WM-266.4 in athymic nude mice expecting than an in vivo environment and 
stimuli to these established melanoma cell lines would lead to an increase in 
the chemokine receptors surface expression that was not detected in the cell 
lines tested. 
When compared with the original cell lines, the WM-115-X and WM-266-X 
tumors obtained after xenotransplantation, as well as the cell lines derived 
from them (WM-115-CX and WM-266-CX) had similar patterns of cell 
surface expression of receptors, that is, minute or no expression was 
observed, without significant differences to the original cell lines. 
WM-115-X and WM-266-X were obtained from collagenase treatment of 
these tumors so we can consider that the disaggregation procedure could 
influence the detection of the receptors at this level, as in the case of the cell 
lines these were detached solely using EDTA to avoid the effect of trypsin 
on the surface cell receptors. 
 
Intracellular expression of chemokine receptors  
When compared with the original cell line, the WM-115-X xenografts, as 
well as the derived WM-115-CX cell lines, showed a substantial increase in 
the expression of CCR7 and CCR10, a considerable decrease in the 
expression of CXCR4 and a slight but significant decrease in the expression 
of CXCR3. CXCR7 showed an increased expression in the WM-115-X 
Results and Discussion 
116 
xenografts that was not observed in the derived WM-115-CX cell lines that 
were not significantly different from the original cell line. (Figure 24A, 
Table 17). WM-266-X xenografts showed a significant decrease of CXCR4 
and significant increases of CXCR7 and CCR7, when compared with the 
original cell line, while the WM-266-CX derived cell lines presented 
increases of CXCR3, CCR7 and CCR10 with respect to the original cell line. 
(Figure 24B, Table 17).  
 
Table 17. Intracellular expression of chemokine receptors after xenotransplantation. 
Mean percentage (%) of cells which significantly expressed (p<0.05) chemokine 
receptors intracellularly; MFI represents the mean fluorescence index calculated as 
the ratio between the mean fluorescence of samples stained with the mAb anti-
receptor and correspondent isotypic control (WM-115-X and WM-266.4-X 
represent the xenografts; WM-115-CX and WM-266.4-CX represent the cell lines 
obtained after culturing the xenografts). 
 
CXCR3 CXCR4 CXCR7 CCR7 CCR10 
% MFI % MFI % MFI % MFI % MFI 
WM-115 88.59 5.40 92.45 3.95 4.97 1.57 20.16 1.70 13.67 1.57 
WM-115-X 59.84 3.46 14.10 1.62 58.89 4.14 75.32 4.10 66.90 3.47 
WM-115-
CX 
76.11 3.95 12.14 1.65 5.44 1.34 82.03 3.44 81.90 3.44 
WM-266 74.08 2.22 96.26 3.39 21.53 1.68 40.16 1.69 24.00 1.63 
WM-266-X 28.19 2.24 6.71 1.26 13.96 2.08 56.31 2.50 28.54 1.83 
WM-266-
CX 
91.65 4.41 94.17 3.74 53.67 2.34 72.95 32.77 88.62 4.60 
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Intracellular expression of chemokines 
In WM-115-X xenografts a general decrease of chemokine expression is 
observed to levels similar to negative controls for most of the studied 
chemokines with respect to the initial WM-115 cell line, as can be detected 
by mean fluorescence index (Table 18). In WM-115-CX lines derived after 
xenotransplantation an increased expression of all chemokines is observed, 
when compared with the original cell line (Figure 25A,  Table 18). In WM-
266-X xenografts, a general decrease of chemokine expression is also 
observed when compared with WM-266.4 cell line, but that does not reach 
negative control values. The WM-266-CX cell lines derived from the 
xenografts only show significant increased expression of CXCL12 and 
CCL19 (Figure 25B, Table 18) with respect to the original cell line. 
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Figure 24. Intracellular expression of chemokine receptors in WM-115 and WM-
266.4 cell lines after xenotransplantation. Comparison between mean intracellular 
expression of chemokine receptors in the original melanoma cell lines WM-115 (a) 
and WM-266.4 (b) and the tumors and cell lines obtained after xenotransplantation. 
Bars refer to standard error (* p<0.05). 
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Figure 25. Intracellular expression of chemokines in WM-115 and WM-266.4 cell 
lines after xenotransplantation. Comparison between mean intracellular expression 
of chemokines in the original melanoma cell lines WM-115 (a) and WM-266.4 (b) 
and the tumors and cell lines obtained after xenotransplantation. Bars refer to 
standard error (* p<0.05). 
 
In our study a selection process seems to take place within the tumoral 
population in the xenograft, especially in the case of WM-115 derived from 
a primary tumor where the changes observed in the intracellular chemokine 
receptors that have been involved in tumoral growth and progression are 
maintained in the derived cell lines in culture medium. However, 
intracellular chemokine levels show a general decrease in the xenografts, 
being more pronounced in WM-115-X than in WM-266-X and that seems to 
be due to environmental causes, as these changes are not maintained in the 
derived cell lines. 
Results and Discussion 
120 
In summary, we find coexpression of chemokine receptors and their ligands 
in human melanoma cell lines. However, this expression is intracellular and 
receptors are not found at the cell membrane nor chemokines are secreted to 
the cell medium. The levels of intracellularly expressed chemokine receptors 
and their ligands show dynamic variations after xenotransplantation that 
differ depending on the origin of the cell line but we still cannot find surface 
expression of the receptor, as we expected. These changes could affect cell 
trafficking assays that correlate in vitro and in vivo data.  
Our results could also have implications in the studies that analyze 
chemokines or chemokine receptors expression in melanomas that do not 
ascertain the cell membrane location of chemokine receptors or the secretion 
of chemokines to the extracellular medium.  
Results and Discussion 
 121 
iii)  Detailed study of 2 cell lines established from WM-115 after 
xenotransplantation 
WM115 vs WM115-CX-SC and WM115-CX-IM 
 
Because of their great increase in the SP there were two cell lines derived 
from tumors of WM-115 cell line that were studied in more detail, especially 
at the CSC and EMT level. These cell lines were established from two 
tumors produced in the same animal, one which arise from sub-cutaneous 
inoculation of WM-115 (hereafter called WM-115-CX-SC) and the other 
which arise from its intra-muscular inoculation (hereafter called WM-115-
CX-IM). 
Regarding the surface expression of melanoma-associated antigens (Table 
19) we could observe in both cell lines a decrease in the subpopulation 
CD146
+
 (concomitant with a decrease in its gene expression) and an increase 
in the Melan-A
+
. Also, genes like gp100, TPRM1 and MAGE1 were slightly 
augmented in both cell lines. Interestingly TYR was extremely 
overexpressed in WM-115-CX-SC but not in WM-115-CX-IM (Figure 26). 
 
Table 19 Expression of Melanoma-associated antigens (MAA) after 
xenoransplantation. Mean percentage (%) of cells which significantly expressed 
(p<0.05) MAA; MFI represents the mean fluorescence index calculated as the ratio 
between the mean fluorescence of samples stained with the mAb anti-MAA and 
correspondent isotypic control (n =3). 
Cell line 
CD61 CD146 Melan-A 
% MFI % MFI % MFI 
WM-115 99.22 129.71 95.85 74.39 82.10 11.08 
WM-115-CX-SC 95.00 37.76 72.45 91.86 95.33 6.36 
WM-115-CX-IM 97.08 37.03 74.26 98.26 98.43 38.01 
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Figure 26. Gene expression of Melanoma-associated antigens (MAA) after 
xenotransplantation. Relative gene expression is presented in a heatmap with the 
ΔCts calculated using RRN18S, PGK1, ACTB and RPL13A as housekeeping genes. 
Red represent genes that are more expressed than green. Genes that were not 
amplified are shown in white.  
 
 
The ABCB1+ subpopulation increased in both cell lines (Table 20) although 
this increase was not seen at the gene level (Figure 27). However, no 
changes were seen for the other ABC transporters tested. Regarding the SP, 
there was an increase in both cell lines although it was more pronounced on 
WM-115-CX-IM (Table 20). Nevertheless, the percentage of SP found in 
this cells line was highly variable between experiments. In Figure 28 can be 
seen an example where 12% of SP was analyzed. 
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Table 20. Surface expression of ABC-transporters and SP after xenotransplantation. 
Mean percentage (%) of cells which significantly expressed (p<0.05) ABC-
transporters; MFI represents the mean fluorescence index calculated as the ratio 
between the mean fluorescence of samples stained with the mAb anti- ABC-
transporter and correspondent isotypic control (n =3). 
Cell line 
ABCB1 ABCB5 ABCG2 % of SP             
(Mean ± SE) 
% MFI % MFI % MFI 
WM-115 13.06 1.91 0.99 1.19 0.79 1.16 0.12 ± 0.04 
WM-115-CX-SC 61.43 4.46 ns ns ns ns 1.27 ± 0.36 
WM-115-CX-IM 45.63 2.53 ns ns ns ns 4.32 ± 0.88 
 
 
 
Figure 27. Gene expression of cancer stem cell markers after xenotransplantation. 
Relative gene expression is presented in a heatmap with the ΔCts calculated using 
RRN18S, PGK1, ACTB and RPL13A as housekeeping genes. Red represent genes 
that are more expressed than green. Genes that were not amplified are shown in 
white.  
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The importance of ABC transporters to the SP, discussed in the previous 
chapter, is corroborated by the increase in SP after xenotransplantation in 
both WM-115-X and WM-266.4-X cell lines. The increase in SP in WM-
115-X cell lines might be related to the increase in ABCG2 gene expression 
as this is the only transporter whose expression increases significantly in 
WM-115-X-IM (ca. 3-fold) when compared with WM-115-X-SC, which in 
turn is reflected in a proportional increase in SP. As for WM-266.4, the 
slight increase in SP observed only in WM-266-X-IM might be related to the 
minor increase in ABCB5 expression, which is the only ABC transporter 
whose gene expression is simultaneously different between WM-266-X-IM 
and the SC and parental cell lines. 
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Figure 28. Side Population found in WM-115-CX-IM 
 
Results and Discussion 
 125 
The CD34+ subpopulation disappeared in both cell lines (Table 21) although 
an increase in its gene level expression was found (Figure 27). On the other 
hand, the parental cell line did not have a CD90+ subpopulation which 
appeared in both cell lines (Table 21, concomitant with an increased gene 
expression, Figure 27). Regarding CD117, although its gene expression was 
increased in both cell lines (Figure 27), only in WM-115-CX-SC showed a 
CD117+ subpopulation (Table 21). CD133 was highly overexpressed in both 
cell lines although this was not seen at the protein level as no CD133+ 
subpopulation was detected (Table 21, Figure 27). 
 
Table 21. Surface expression of commonly used CSC markers after 
xenotransplantation. Mean percentage (%) of cells which significantly expressed 
(p<0.05) CSC markers; MFI represents the mean fluorescence index calculated as 
the ratio between the mean fluorescence of samples stained with the mAb anti-CSC 
marker and correspondent isotypic control (n =3).  
Cell line 
CD34 CD90 CD117 CD133 
% MFI % MFI % MFI % MFI 
WM-115 2.75 0.98 ns ns ns ns ns ns 
WM-115-CX-SC ns ns 6.80 1.63 1.45 0.98 ns ns 
WM-115-CX-IM ns ns 10.44 2.24 ns ns ns ns 
 
 
Regarding the neuronal stem cell markers tested, changes were found in 
TUJ1 (Table 22, Figure 29). Although there was no increase at the gene 
level, a TUJ1+ subpopulation was found in WM-115-CX-SC. Also, CD271 
gene expression slightly increased in WM-115-CX-SC. 
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Table 22. Expression of neuronal stem cell markers after xenotransplantation. Mean 
percentage (%) of cells which significantly expressed (p<0.05) these CSC markers; 
MFI represents the mean fluorescence index calculated as the ratio between the 
mean fluorescence of samples stained with the mAb anti-CSC marker and 
correspondent isotypic control (n =3).  
Cell line 
TUJ1 Nestin CD271 
% MFI % MFI % MFI 
WM-115 ns ns 98.58 320.23 70.84 17.56 
WM-115-CX-SC 6.39 1.47 98.34 146.11 58.31 18.55 
WM-115-CX-IM ns ns 91.56 77.70 63.99 9.75 
 
 
 
Figure 29. Gene expression of neuronal stem cell markers after xenotransplantation. 
Relative gene expression is presented in a heatmap with the ΔCts calculated using 
RRN18S, PGK1, ACTB and RPL13A as housekeeping genes. Red represent genes 
that are more expressed than green. Genes that were not amplified are shown in 
white.  
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As for gene expression of pluripotency stem cell markers, there is a slight 
increase in the gene expression of OCT-4, NANOG, SOX-2 and caspase-3 in 
WM-115-CX-IM, while DDPA5 was not detected in this cell line and had 
comparable level of expression in WM-115-CX-SC (Figure 30). 
 
Figure 30. Gene expression of pluripotency stem cell markers after 
xenotransplantation. Relative gene expression is presented in a heatmap with the 
ΔCts calculated using RRN18S, PGK1, ACTB and RPL13A as housekeeping genes. 
Red represent genes that are more expressed than green. Genes that were not 
amplified are shown in white.  
 
There was a slight decrease in the percentage of the N-cadherin+ 
subpopulation found in WM-115-CX-SC. As for E-cadherin, a small 
subpopulation was found in both cell lines, although no gene expression was 
detected (Table 23, Figure 31). Regarding the gene expression of the cell 
adhesion molecules, EpCAM slightly increased in both cell lines and VCAM 
was highly increased while NCAM and AlCAM were slightly overexpressed 
only in WM-115-CX-IM (Figure 20). 
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Table 23. Surface expression of EMT markers after xenotransplantation. Mean 
percentage (%) of cells which significantly expressed (p<0.05) these EMT markers; 
MFI represents the mean fluorescence index calculated as the ratio between the 
mean fluorescence of samples stained with the mAb anti-EMT marker and 
correspondent isotypic control (n =3).  
Cell line 
Ncad Ecad 
% MFI % MFI 
WM-115 39.34 3.66 0.65 1.18 
WM-115-CX-SC 21.49 2.42 3.37 2.37 
WM-115-CX-IM 36.76 2.16 3.62 1.70 
 
 
It has been shown by others that E-cadherin loss is often associated with 
CD146 increases (Haass et al. 2005) which is in accordance with our gene 
expression data.  
As can be seen in Figure 31 the rest of the genes related to EMT (SPARC, 
SPP1, SNAI1, SNAI2 and VIM) were slightly underexpressed when 
compared to the parental cell line with the exception of FN1 which was 
slightly overexpressed in WM-115-CX-SC. 
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Figure 31. Gene expression of EMT  markers after xenotransplantation. Relative 
gene expression is presented in a heatmap with the ΔCts calculated using RRN18S, 
PGK1, ACTB and RPL13A as housekeeping genes. Red represent genes that are 
more expressed than green. Genes that were not amplified are shown in white.  
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3. Xenografts versus human melanoma cell lines 
 
The validity of a model used to study a biological question in the context of 
cancer, depends on how faithfully it reproduces the characteristic of the 
tumor. Although cancer cell lines are a common experimental model as they 
provide reproducible results (if used within the same range of passages and 
with the same protocol) they are limited because they have been established 
on the late time in the history of the original cancer they were derived from 
and, therefore, represent one time point of the tumor and not its dynamic 
evolution over time.  
 
In this study we used thirteen established human melanoma cell lines, five 
established from primary tumors and eight established from metastases at 
different locations (skin, brain, lymph nodes and lung). In summary, if we 
analyse the gene expression of all the quantified genes in this study (Figure 
32) it is obvious that there is no specific pattern of gene expression for 
primary and metastatic cell lines. On the contrary, we can appreciate the 
variability of the gene expression between all the cell lines. 
 
Xenotransplantation models, based on immunocompromised mice, are 
particularly successful in mimicking advanced, metastatic melanoma as their 
diminished ability to mount an effective immune response allows the growth 
of human melanomas and the expression of malignant properties (Zaidi et al. 
2008). It is commonly accepted that the function of cell adhesion molecules, 
and most of the intervenients in cancer formation and spreading, is 
profoundly influenced by the extracellular environment. Therefore, 
melanoma invasion should be examined under more physiological 
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conditions, namely using xenografts models, which are able to provide a 
history sequence and provide a more physiological microenvironment for 
human cells (van Starveren et al. 2009). 
 
Figure 32. Gene expression in human melanoma cell lines of all tested genes. 
Relative gene expression is is presented in a heatmap with the ΔCts calculated using 
RRN18S, PGK1, ACTB, RPL13A and B2M as housekeeping genes. Red represent 
genes that are more expressed than green. Genes that were not amplified are shown 
in white.  
 
Primary Metastasis 
Results and Discussion 
132 
A comparative analysis of global gene expression has been performed 
elsewhere between human melanoma cell lines with different metastatic 
capacity and the xenografts obtained by their subcutaneous injection into 
immunocompromised mice, demonstrating extensive differential expression 
between both models (Xi et al. 2008). These variations can be due to 
selection of determined subpopulations with different tumorigenic capacity 
or to the effect of the different microenvironment within the nude mouse. 
In this study we used an athymic nude mice model to perform the 
xenografts. These mice are not severely immunocompromised, they lack T 
cells but the B cells, dendritic cells and granulocytes are all relatively intact, 
and there is a compensatory increase in both natural killer (NK)-cell activity 
and tumoricidal macrophages in these mice. Then, it is expectable that, by 
the time we removed the tumors, they have already escaped immune 
surveillance and cell killing by the immune cells. 
Analysing collectively all the data regarding the xenotransplants (i.e., 
WM115 vs WM115-CX-SC and WM115-CX-IM), we can appreciate 
significant changes both at protein and gene level. 
The ABCB1+ subpopulation increased in both cell lines (Table 20) although 
this increase was not seen at the gene level (Figure 27). Regarding the SP, 
there was an increase in both cell lines although being more pronounced on 
WM-115-CX-IM (Table 20). This increase might be related to the increase 
in ABCG2 gene expression as this is the only transporter whose expression 
increases significantly in WM-115-X-IM. Furthermore, the parental cell line 
did not have a CD90+ subpopulation which appeared in both cell lines 
(Table 21, concomitant with an increased gene expression, Figure 27). 
Regarding CD117, although its gene expression was increased in both cell 
lines (Figure 27), only in WM-115-CX-SC showed a CD117+ subpopulation 
(Table 21). CD133 was highly overexpressed in both cell lines although this 
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was not seen at the protein level as no CD133+ subpopulation was detected 
(Table 21, Figure 27). As for gene expression of pluripotency stem cell 
markers, there is a slight increase in the gene expression of OCT-4, 
NANOG, SOX-2 and caspase-3 in WM-115-CX-IM. Concerning EMT 
marker, there was a slight decrease in the percentage of the N-cadherin+ 
subpopulation found in WM-115-CX-SC. As for E-cadherin, a small 
subpopulation was found in both cell lines, although no gene expression was 
detected (Table 23, Figure 31). Regarding the gene expression of the cell 
adhesion molecules, EpCAM slightly increased in both cell lines and VCAM 
was highly increased while NCAM and AlCAM were slightly overexpressed 
only in WM-115-CX-IM (Figure 20). 
In summary, the cell lines stablished after transplantation are different from 
the parental cell lines, having increased levels of CSC markers, pluripotency 
stem markers and EMT markers (specially adhesion molecules). 
Furthermore, slight different patterns can be found depending on the 
injection site. 
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Conclusions 
 
1. Flow cytometry and real-time PCR allow the characterisation of 
human melanoma cell lines established from different origins 
(primary or metastatic tumor) reflecting the heterogeneity of human 
melanoma. 
 
2. With the markers studied we could not find a correlation between 
the pattern of expression and the origin of the cell line (primary or 
metastatic tumor). 
 
3. The selective pressure exerted by the athymic nude mice 
microenvironment produced important variations in the gene and 
protein expression profiles of the human melanoma cell lines 
transplanted. The variations obtained depend on the location of cell 
inoculation (subcutaneous or intramuscular). 
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Introducción 
El melanoma es el tipo de cáncer de piel más agresivo. Ocurre en los 
melanocitos, células productoras de melanina ubicadas en la capa inferior de 
la epidermis, en la piel. El melanoma puede propagarse a través del tejido 
creciendo en áreas cercanas. Cuando las células tumorales se separan del 
tumor primario y viajan a través del sistema linfático o de la sangre para 
otras partes del cuerpo donde se establecen y empiezan a formar un tumor 
metastásico, se denomina metástasis. La metástasis generalizada es la 
principal causa de muerte en el melanoma.  
Los cánceres surgen a través de la adquisición de mutaciones que suprimen 
la senescencia y promueven la división celular, pero hay distintos modelos 
para explicar el crecimiento del tumor. El modelo clonal o estocástico afirma 
que se producen cambios (epi)genéticos en todas las células tumorales al 
largo del tiempo, y que hay una selección natural gradual de las células más 
aptas y más agresivas. El modelo de las células madre tumorales sugiere 
que sólo una subpoblación de células dentro del tumor, las células madre 
tumorales, o en el caso del melanoma, las células iniciadores del melanoma, 
tienen la capacidad de regenerarse y mantener un tumor in vivo. La mayor 
parte de la población de células tumorales es heterogénea,  no comparte estas 
propiedades y carece de la capacidad de ser tumorigénicos.  
Un proceso importante para la progresión del melanoma y la ocurrencia de  
metástasis es la transición epitelio-mesenquica. Este proceso se caracteriza 
por la pérdida de adhesión celular, la represión en la expresión de E-
cadherina resultando en el aumento de la movilidad celular. 
En el melanoma la metástasis ocurre preferencialmente hacia el cerebro, 
pulmón, hígado y piel. Esta selectividad de la metástasis por determinados 
órganos viene determinada por consideraciones anatómicas de flujo 
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sanguíneo, por propiedades intrínsecas de las células tumorales y por 
propiedades intrínsecas del órgano diana. La interacción quimiocina-
receptor puede inducir señales que no solo actúen sobre la movilidad celular 
hacia un gradiente, sino que las quimiocinas pueden jugar papeles 
alternativos sobre la adhesión de las células tumorales, la invasión, la 
supervivencia, el crecimiento tumoral y la angiogénesis. 
El melanoma es un tumor heterogéneo a nivel genético, morfológico y 
antigénico. Las líneas celulares muestran células con distinta morfología  
incluyendo formas ovales pequeñas, fusiformes, poligonales planas y 
grandes con formas dendríticas. La expresión antigénica es también muy 
heterogénea, pudiendo distinguirse subpoblaciones celulares de distinto 
tamaño con distintos marcadores antigénicos. Esta expresión puede ser 
dinámica, variando con la superficie de cultivo celular, cambios de medio, 
densidad celular y duración del cultivo. Otro modelo comúnmente usado en 
el estudio del melanoma es un modelo animal de xenotransplante. En este 
modelo, muestras humanas de melanoma (provenientes de pacientes o de 
líneas celulares) son trasplantadas en ratones atímicos inmunodeficientes 
que, al tener un sistema inmunitario defectuoso, permiten el crecimiento de 
las células tumorales y la expresión de sus propiedades. 
 
Hipótesis y Objetivos 
El melanoma cutáneo humano es una neoplasia altamente heterogénea 
compuesta por subpoblaciones de células tumorales con fenotipos 
moleculares y biológicos distintos. Estas distintas subpoblaciones son la base 
de una complejidad biológica que incluye los fenómenos de auto-
renovación, diferenciación, iniciación tumoral, progresión y resistencia a 
terapia.  
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En este trabajo se plantean las siguientes hipótesis: 
La utilización de líneas celulares de melanoma humano permite determinar 
la heterogeneidad intra- e inter-tumoral mediante la cuantificación de las 
proteínas que intervienen en los procesos anteriormente mencionados 
utilizando técnicas cuantitativas de citometría de flujo y PCR-cuantitativa en 
líneas celulares procedentes del tumor primario o de la metástasis. 
El xenotransplante de las líneas celulares a ratones  atímicos 
inmunodeficientes permite establecer las subpoblaciones celulares y 
variaciones de expresión génica que se seleccionen preferentemente en los 
tumores, cuando estos se desarrollan en ratones dentro de  un microambiente 
más similar al que existía en el paciente afectado. 
 
En este marco, se proponen los siguientes objetivos:  
- Caracterizar fenotípica y funcionalmente, mediante análisis citómico y 
cuantificación de la expresión génica, los antígenos de melanoma, 
marcadores de células madre tumorales, de pluripotencia y del proceso de 
transición epitelio mesenquina, en distintas líneas celulares de melanoma 
humano, obtenidas a partir de melanomas primarios y de metástasis. 
- Caracterizar fenotípica y funcionalmente, mediante análisis citómico y 
cuantificación de la expresión génica, los sistemas formados por los 
receptores de quimiocinas CXCR3, CXCR4, CXCR7, CCR7 y CCR10 y 
respectivas quimiocinas ligando, en distintas líneas celulares de melanoma 
humano, obtenidas a partir de melanomas primarios y de metástasis. 
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- Comprender las variaciones fenotípicas y de expresión génica que se 
seleccionan preferentemente en los tumores, cuando estos se desarrollan en 
ratones sobre la presión del microambiente. 
- Correlacionar los resultados obtenidos con el origen del melanoma, 
primario o metástasis. 
 
Metodología 
1. Muestras biológicas 
- Líneas celulares de melanoma humano: MeWo, A-375, SK-MEL-2, SK-
MEL-28, Malme-3M (ATCC); WM-266, WM-115 (ECACC); Mel-HO, 
Mel-Juso, IPC-298, IGR37, IGR39 (DSMZ) y Mel-RC08 (Departamento de 
Patología, Universitad de Valencia). WM-115, Mel-HO, Mel-Juso, IPC-298 
y IGR39 son líneas establecidas a partir de tumores primarios mientras que 
MeWo, A-375, SK-MEL-2, SK-MEL-28, Malme-3M, WM-266, IGR37 y 
Mel-RC08 son líneas establecidas a partir de tumores primarios. 
- Xenotransplantes (de WM-115 y WM-266) y sus líneas derivadas. 
 
2. Cuantificación de proteínas por citometría de flujo: 
- Caracterización inmunofenotipica por citometría de flujo de antígenos de 
melanoma, marcadores de células madre tumorales, característicos de la 
transición epitelio-mesenquima y de quimiocinas y sus receptores (Tabla 2A 
y 2B). 
- Análisis de la side population. 
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3. Cuantificación de la expresión génica, por PCR cuantitativa: 
- Aislamiento y control de calidad del ARN aislado de las líneas celulares. 
- Cuantificación de los distintos genes listados (Tabla 5). 
 
4. Análisis estadístico: 
- El análisis estadístico de las cuantificaciones de proteína por citometría de 
flujo se hijo con test t de student. 
- Los datos de expresión génica se refieren a ∆Cts y se presentan en 
heatmaps producidos con el programa R (package Heatmap3). 
- La correlación entre los datos de cuantificación de proteína y de expresión 
génica se realizaron con Graphpad prism usando la correlación de Spearman. 
 
Resultados 
Se han caracterizado 13 líneas de melanoma humano, 5 con origen primario 
y 8 con origen en metástasis de distintas localizaciones (piel, cerebro, 
nódulos linfáticos y pulmón).  
Hemos encontrado un perfil de expresión de antígenos de melanoma, 
marcadores de células madre tumorales, característicos de la transición 
epitelio-mesénquima y de quimiocinas muy heterogéneo. Además, 
analizando el perfil de todos los genes cuantificados es perceptible que no 
hay un patrón específico de expresión génica que caracterice y distinga las 
células primarias de las metastáticas. Al revés, se puede apreciar la 
variabilidad y heterogeneidad que existe entre las distintas líneas estudiadas. 
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Con relación al sistema quimiocinas-receptor, comprobamos que la 
expresión de receptores es intracelular y no ocurre en la superficie de las 
células. Verificamos también que los niveles de expresión de los receptores 
de quimiocinas y sus ligandos sufren variaciones dinámicas tras la 
xenotrasplantación, que son distintas dependiendo del origen de la línea 
trasplantada. Sin embargo, no se ha detectad la expresión de superficie de los 
receptores de quimiocinas, como esperado. 
Analizando colectivamente los datos relativos al xenotransplante (i.e., 
WM115 vs WM115-CX-SC and WM115-CX-IM), se pueden apreciar 
importantes cambios a nivel de proteína y de expresión génica. La 
subpoblación ABCB1+ ha incrementado en ambas las líneas y con relación a 
la SP se produjo un aumento en ambas las líneas, más significativo en WM-
115-CX-IM (Table 20). Este se puede deber a un gran aumento en la 
expresión génica de ABCG2. Además, la línea parental no tenía una 
subpoblación CD90+ que apareció en las dos líneas trasplantadas. De igual 
forma se produjo un aumento de la expresión génica de CD117 y CD133 
(Table 21, Figure 27). También se produjeron aumentos en la expresión de 
genes de pluripotencia y característicos de la transición epitélio-mesenquima 
(en concreto de algunas moléculas de adhesión). Los patrones de expresión 
génica fueron distintos dependiendo del local de inoculación de las células 
en el ratón (subcutáneo o intramuscular). 
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Conclusiones 
- Las técnicas cuantitativas de citometría de flujo y de PCR en tiempo real 
permitieron caracterizar el perfil de expresión de distintos marcadores, a 
nivel proteico y genético, en distintas líneas celulares de melanoma humano, 
obtenidas a partir de melanomas primarios y de metástasis, reflejando la 
heterogeneidad del melanoma humano. 
- Los marcadores estudiados no se correlacionan con el origen del tumor 
(primario o metástasis). 
- La presión selectiva de microambiente del ratón produce importantes 
cambios en los patrones de expresión génica y de proteína, que son distintos 
dependiendo del local de inoculación de las células en el ratón (subcutáneo o 
intramuscular). 
